BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31. [PMID: 14699483 DOI: 10.1053/j.gastro.2003.10.047] [Cited by in Crossref: 638] [Cited by in F6Publishing: 556] [Article Influence: 35.4] [Reference Citation Analysis]
Number Citing Articles
1 Lightner AL, Mckenna NP, Alsughayer A, Harmsen WS, Taparra K, Parker ME, Raffals LE, Loftus EV. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn’s Disease: Are There Differences in the Safety Profiles? Diseases of the Colon & Rectum 2019;62:1352-62. [DOI: 10.1097/dcr.0000000000001482] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
2 Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheumatic Disease Clinics of North America 2004;30:237-55. [DOI: 10.1016/j.rdc.2004.02.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
3 Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628-1640. [PMID: 19664627 DOI: 10.1053/j.gastro.2009.07.062] [Cited by in Crossref: 361] [Cited by in F6Publishing: 331] [Article Influence: 27.8] [Reference Citation Analysis]
4 Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Dig Dis Sci. 2015;60:951-956. [PMID: 25326115 DOI: 10.1007/s10620-014-3392-z] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 11.1] [Reference Citation Analysis]
5 Uchino M, Ikeuchi H, Matsuoka H, Tsuchida T, Tomita N, Takesue Y. Risk factors associated with surgical site infection after ileal pouch-anal anastomosis in ulcerative colitis. Dis Colon Rectum 2010;53:143-9. [PMID: 20087088 DOI: 10.1007/DCR.0b013e3181bb0d1d] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
6 Yang SK. How Does the Epidemiology of Inflammatory Bowel Disease Differ between East and West? A Korean Perspective. Inflamm Intest Dis. 2017;2:95-101. [PMID: 30018960 DOI: 10.1159/000454712] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
7 Biancone L, Cretella M, Tosti C, Palmieri G, Petruzziello C, Geremia A, Calabrese E, Pallone F. Local injection of infliximab in the postoperative recurrence of Crohn's disease. Gastrointestinal Endoscopy 2006;63:486-92. [DOI: 10.1016/j.gie.2005.08.047] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
8 Teshima CW, Thompson A, Dhanoa L, Dieleman LA, Fedorak RN. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009;23:348-52. [PMID: 19440565 DOI: 10.1155/2009/180840] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
9 Tougeron D, Mauillon J, Tranvouez J. Une varicelle grave lors d’un traitement par infliximab pour maladie de Crohn. Gastroentérologie Clinique et Biologique 2006;30:1410-3. [DOI: 10.1016/s0399-8320(06)73573-4] [Cited by in Crossref: 10] [Article Influence: 0.6] [Reference Citation Analysis]
10 Bollegala N, Jackson TD, Nguyen GC. Increased Postoperative Mortality and Complications Among Elderly Patients With Inflammatory Bowel Diseases: An Analysis of the National Surgical Quality Improvement Program Cohort. Clin Gastroenterol Hepatol 2016;14:1274-81. [PMID: 26656299 DOI: 10.1016/j.cgh.2015.11.012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
11 Bermejo F, San Román AL, Algaba A, Van Domselaar M, Carneros JA, Rivero M, Piqueras B, Paz Valer M. Eficacia de la premedicación con un esteroide y un antihistamínico en la prevención de reacciones infusionales por infliximab. Gastroenterología y Hepatología 2008;31:629-32. [DOI: 10.1016/s0210-5705(08)75809-6] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
12 Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM; Swiss IBD Cohort Study Group. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. Eur J Gastroenterol Hepatol 2018;30:612-20. [PMID: 29384798 DOI: 10.1097/MEG.0000000000001078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
13 Lahat A, Lang A, Ben-Horin S. Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion. 2012;85:1-8. [PMID: 22095142 DOI: 10.1159/000332079] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
14 Ji XQ, Wang LX, Lu DG. Pulmonary manifestations of inflammatory bowel disease. World J Gastroenterol 2014; 20(37): 13501-13511 [PMID: 25309080 DOI: 10.3748/wjg.v20.i37.13501] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
15 Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther 2010;31:553-60. [PMID: 20002026 DOI: 10.1111/j.1365-2036.2009.04206.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
16 Li J, Zhang Z, Wu X, Zhou J, Meng D, Zhu P. Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis. Front Pharmacol 2021;12:746396. [PMID: 34790122 DOI: 10.3389/fphar.2021.746396] [Reference Citation Analysis]
17 Roccetti M, Marfia G, Salomoni P, Prandi C, Zagari RM, Gningaye Kengni FL, Bazzoli F, Montagnani M. Attitudes of Crohn's Disease Patients: Infodemiology Case Study and Sentiment Analysis of Facebook and Twitter Posts. JMIR Public Health Surveill 2017;3:e51. [PMID: 28793981 DOI: 10.2196/publichealth.7004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 5.2] [Reference Citation Analysis]
18 Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-790. [PMID: 16979537 DOI: 10.1016/j.berh.2006.06.002] [Cited by in Crossref: 153] [Cited by in F6Publishing: 132] [Article Influence: 10.2] [Reference Citation Analysis]
19 Itaba S, Iwasa T, Sadamoto Y, Nasu T, Misawa T, Inoue K, Shimokawa H, Nakamura K, Takayanagi R. Pneumocystis Pneumonia During Combined Therapy of Infliximab, Corticosteroid, and Azathioprine in a Patient with Crohn’s Disease. Dig Dis Sci 2007;52:1438-41. [DOI: 10.1007/s10620-006-9575-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
20 Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Danielsson A, Verbaan H. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811. [PMID: 15940615 DOI: 10.1053/j.gastro.2005.03.003] [Cited by in Crossref: 734] [Cited by in F6Publishing: 651] [Article Influence: 43.2] [Reference Citation Analysis]
21 Irving PM, Gibson PR. Infliximab: Getting the most for your money. J Gastroenterol Hepatol 2007;22:1559-61. [DOI: 10.1111/j.1440-1746.2007.05003.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Baraliakos X, Braun J. Spondyloarthritides. Best Practice & Research Clinical Rheumatology 2011;25:825-42. [DOI: 10.1016/j.berh.2011.11.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
23 Bagul A. Ischaemic/reperfusion injury: Role of infliximab. World J Transplant 2012; 2(3): 35-40 [PMID: 24175194 DOI: 10.5500/wjt.v2.i3.35] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Criado PR, Criado RFJ, Vasconcellos C, Ramos RDO, Gonçalves AC. Reações cutâneas graves adversas a drogas: aspectos relevantes ao diagnóstico e ao tratamento - Parte II. An Bras Dermatol 2004;79:587-601. [DOI: 10.1590/s0365-05962004000500010] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
25 Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease? Ann Gastroenterol 2018;31:413-24. [PMID: 29991886 DOI: 10.20524/aog.2018.0253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
26 Dotson J, Crandall W, Bout-Tabaku S. Exploring the differential diagnosis of joint complaints in pediatric patients with inflammatory bowel disease. Curr Gastroenterol Rep 2011;13:271-8. [PMID: 21298374 DOI: 10.1007/s11894-011-0181-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
27 Balog A, Klausz G, Gál J, Molnár T, Nagy F, Ocsovszky I, Gyulai Z, Mándi Y. Investigation of the Prognostic Value of TNF-α Gene Polymorphism among Patients Treated with Infliximab, and the Effects of Infliximab Therapy on TNF-α Production and Apoptosis. Pathobiology 2004;71:274-80. [DOI: 10.1159/000080062] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
28 Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103:937-943. [PMID: 18177449 DOI: 10.1111/j.1572-0241.2007.01718.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 5.2] [Reference Citation Analysis]
29 Said JT, Elman SA, Merola JF. Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders. Ann Transl Med 2021;9:430. [PMID: 33842651 DOI: 10.21037/atm-20-5552] [Reference Citation Analysis]
30 Weber RW. Adverse reactions to biological modifiers. Curr Opin Allergy Clin Immunol. 2004;4:277-283. [PMID: 15238793 DOI: 10.1097/01.all.0000136757.58818.10] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
31 Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med 2014;46:547-54. [PMID: 25105206 DOI: 10.3109/07853890.2014.941919] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
32 Mui M, An V, Lovell J, D’souza B, Woods R. Patients’ perspective on bowel resection for inflammatory bowel disease. Int J Colorectal Dis 2018;33:219-22. [DOI: 10.1007/s00384-017-2941-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
33 Shen B. Impact of preoperative infliximab use on postoperative infectious complications in ulcerative colitis: The price we have to pay?: . Inflammatory Bowel Diseases 2008;14:1019-21. [DOI: 10.1002/ibd.20407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
34 Lew D, Yoon SM, Yan X, Robbins L, Haritunians T, Liu Z, Li D, McGovern DP. Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients. World J Gastroenterol 2017; 23(40): 7265-7273 [PMID: 29142473 DOI: 10.3748/wjg.v23.i40.7265] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
35 Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19-30. [PMID: 17944997 DOI: 10.1111/j.1365-2036.2007.03553.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 4.6] [Reference Citation Analysis]
36 Shirwaikar Thomas A, Schwartz M, Quigley E. Gastrointestinal lymphoma: the new mimic.BMJ Open Gastroenterol. 2019;6:e000320. [PMID: 31645987 DOI: 10.1136/bmjgast-2019-000320] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
37 Berns M, Hommes DW. Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opinion on Investigational Drugs 2016;25:129-43. [DOI: 10.1517/13543784.2016.1126247] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
38 Beaugerie L, Pardi DS. Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature. Aliment Pharmacol Ther. 2005;22:277-284. [PMID: 16097993 DOI: 10.1111/j.1365-2036.2005.02561.x] [Cited by in Crossref: 161] [Cited by in F6Publishing: 127] [Article Influence: 9.5] [Reference Citation Analysis]
39 Lee SJ, Kavanaugh A. Biologic agents in rheumatology: safety considerations. Rheum Dis Clin North Am 2006;32 Suppl 1:3-10. [PMID: 17410696 DOI: 10.1016/s0889-857x(07)70003-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
40 Afif W, Loftus EV. Safety profile of IBD therapeutics: infectious risks. Med Clin North Am. 2010;94:115-133. [PMID: 19944801 DOI: 10.1016/j.mcna.2009.08.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
41 Rutgeerts P, van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610. [DOI: 10.1053/j.gastro.2004.02.070] [Cited by in Crossref: 290] [Cited by in F6Publishing: 256] [Article Influence: 16.1] [Reference Citation Analysis]
42 Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to patients: Review: communicating risks of IBD therapy. Alimentary Pharmacology & Therapeutics 2011;33:23-32. [DOI: 10.1111/j.1365-2036.2010.04489.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 6.0] [Reference Citation Analysis]
43 van der Have M, Belderbos TD, Fidder HH, Leenders M, Dijkstra G, Peters CP, Eshuis EJ, Ponsioen CY, Siersema PD, van Oijen MG, Oldenburg B;  Dutch Initiative on Crohn and Colitis (ICC). Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. Dig Liver Dis. 2014;46:881-886. [PMID: 25081843 DOI: 10.1016/j.dld.2014.07.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
44 Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther 2014;39:459-77. [PMID: 24405149 DOI: 10.1111/apt.12616] [Cited by in Crossref: 97] [Cited by in F6Publishing: 82] [Article Influence: 12.1] [Reference Citation Analysis]
45 de Vries HS, van Oijen MG, Driessen RJ, de Jong EM, Creemers MC, Kievit W, de Jong DJ. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol 2011;71:7-19. [PMID: 21143496 DOI: 10.1111/j.1365-2125.2010.03760.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
46 Rudolph SJ, Weinberg DI, Mccabe RP. Long-Term Durability of Crohn’s Disease Treatment with Infliximab. Dig Dis Sci 2008;53:1033-41. [DOI: 10.1007/s10620-007-9969-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
47 Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand J Gastroenterol 2006;41:1064-72. [PMID: 16938720 DOI: 10.1080/00365520600609941] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
48 Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin Drug Saf 2006;5:9-16. [PMID: 16370952 DOI: 10.1517/14740338.5.1.9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
49 Freeman HJ, Perry T, Webber DL, Chang SD, Loh MY. Mucinous carcinoma in Crohn’s disease originating in a fistulous tract. World J Gastrointest Oncol 2010; 2(7): 307-310 [PMID: 21160662 DOI: 10.4251/wjgo.v2.i7.307] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
50 Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006;35:821-36. [PMID: 17129815 DOI: 10.1016/j.gtc.2006.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
51 Alkhawajah MM, Caminero AB, Freeman HJ, Oger JJ. Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know! Mult Scler 2013;19:259-65. [PMID: 23027881 DOI: 10.1177/1352458512461393] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
52 Herrlinger KR, Jewell DP. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2006;24:1403-12. [PMID: 17081161 DOI: 10.1111/j.1365-2036.2006.03147.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
53 Hyman NH. What’s new in colon and rectal surgery. Journal of the American College of Surgeons 2004;199:917-23. [DOI: 10.1016/j.jamcollsurg.2004.08.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
54 Mühl H, Pfeilschifter J. Interleukin-18 bioactivity: a novel target for immunopharmacological anti-inflammatory intervention. Eur J Pharmacol. 2004;500:63-71. [PMID: 15464021 DOI: 10.1016/j.ejphar.2004.07.012] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 3.2] [Reference Citation Analysis]
55 Samimi R, Flasar MH, Kavic S, Tracy K, Cross RK. Outcome of medical treatment of stricturing and penetrating Crohn’s disease: a retrospective study. Inflamm Bowel Dis. 2010;16:1187-1194. [PMID: 19902541 DOI: 10.1002/ibd.21160] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
56 Sartor R. Episodic retreatment versus scheduled maintenance therapy of Crohn’s disease with infliximab: Not so far apart. Gastroenterology 2004;126:598-601. [DOI: 10.1053/j.gastro.2003.12.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
57 Martín De Carpi J, Varea V. Respuesta a la suspensión de azatioprina en pacientes con enfermedad de Crohn en terapia combinada con infliximab. Anales de Pediatría 2009;70:271-7. [DOI: 10.1016/j.anpedi.2008.09.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8:223-40. [PMID: 24490595 DOI: 10.1586/17474124.2014.881715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
59 Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55 Suppl 1:i16-35. [PMID: 16481629 DOI: 10.1136/gut.2005.081950b] [Cited by in Crossref: 423] [Cited by in F6Publishing: 365] [Article Influence: 26.4] [Reference Citation Analysis]
60 Salavert M, Bastida G, Pemán J, Nos P. [Opportunistic co-infection in a patient with Crohn's disease during infliximab (anti-TNFalpha) therapy]. Rev Iberoam Micol 2009;26:213-7. [PMID: 19635442 DOI: 10.1016/j.riam.2009.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
61 Caprilli R, Angelucci E, Cocco A. Early or late guided missile in the treatment of Crohn's disease? Dig Liver Dis 2005;37:973-9. [PMID: 16169305 DOI: 10.1016/j.dld.2005.07.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
62 Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy. Mayo Clinic Proceedings 2008;83:181-94. [DOI: 10.4065/83.2.181] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
63 Hamzaoglu H, Cooper J, Alsahli M, Falchuk KR, Peppercorn MA, Farrell RJ. Safety of infliximab in Crohn's disease: a large single-center experience. Inflamm Bowel Dis. 2010;16:2109-2116. [PMID: 20848473 DOI: 10.1002/ibd.21290] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
64 Kierkus J, Szymanska E, Oracz G, Wiernicka A, Dadalski M. Profile of infliximab in the treatment of pediatric Crohn's disease. Pediatric Health Med Ther 2015;6:79-85. [PMID: 29388577 DOI: 10.2147/PHMT.S64943] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Lie MRKL, Paulides E, van der Woude CJ. Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. Int J Colorectal Dis 2020;35:1489-500. [PMID: 32592091 DOI: 10.1007/s00384-020-03663-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:240-248. [PMID: 23295276 DOI: 10.1038/ajg.2012.406] [Cited by in Crossref: 110] [Cited by in F6Publishing: 89] [Article Influence: 12.2] [Reference Citation Analysis]
67 Arnold TM, Sears CR, Hage CA. Invasive fungal infections in the era of biologics. Clin Chest Med 2009;30:279-86, vi. [PMID: 19375634 DOI: 10.1016/j.ccm.2009.02.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
68 Bhatia JK, Korelitz BI, Panagopoulos G, Lobel E, Mirsky F, Sultan K, DiSanti W, Chun A, Keenan G, Mamun K. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. J Clin Gastroenterol 2007;41:677-81. [PMID: 17667052 DOI: 10.1097/MCG.0b013e31802c2a23] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
69 Shi Z, Ma X, Wu H, Qin X, Qian Q, Zhang W. Effect of acupuncture-moxibustion on TNF-α, sTNFR-I and sTNFR-II of rats with Crohn’s disease. J Acupunct Tuina Sci 2009;7:29-32. [DOI: 10.1007/s11726-009-0029-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Singer NG, Scalzi LV. Remittive agents in pediatric rheumatology: . Current Opinion in Rheumatology 2004;16:571-6. [DOI: 10.1097/01.bor.0000130285.72309.ab] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
71 Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol 2007;7:393-403. [PMID: 17873578 DOI: 10.1097/ACI.0b013e3282ef96df] [Cited by in Crossref: 34] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
72 Val JHD. Old-age inflammatory bowel disease onset: A different problem? World J Gastroenterol 2011; 17(22): 2734-2739 [PMID: 21734781 DOI: 10.3748/wjg.v17.i22.2734] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
73 Yassin S, Isakov NF, Ron Y, Cohen NA, Hirsch A, Maharshak N. A watchful waiting approach for newly diagnosed Crohn's disease patients with an inflammatory phenotype. Int J Colorectal Dis 2021;36:735-43. [PMID: 33404768 DOI: 10.1007/s00384-020-03811-8] [Reference Citation Analysis]
74 Assi K, Pillai R, Gómez-Muñoz A, Owen D, Salh B. The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis. Immunology 2006;118:112-21. [PMID: 16630028 DOI: 10.1111/j.1365-2567.2006.02349.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 5.0] [Reference Citation Analysis]
75 Gomollón F, Gisbert JP. [Must immunomodulators be added to biological treatment in inflammatory bowel disease?]. Gastroenterol Hepatol 2010;33:43-53. [PMID: 19616870 DOI: 10.1016/j.gastrohep.2009.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
76 Stallmach A, Hagel S, Gharbi A, Settmacher U, Hartmann M, Schmidt C, Bruns T. Medical and surgical therapy of inflammatory bowel disease in the elderly - prospects and complications. J Crohns Colitis. 2011;5:177-188. [PMID: 21575879 DOI: 10.1016/j.crohns.2011.02.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
77 Magno Pereira V, Andrade C, Figueira R, Faria G, Jasmins L. Infliximab-Induced Lupus: A Case Report. GE Port J Gastroenterol 2017;24:84-8. [PMID: 29255743 DOI: 10.1159/000450877] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
78 Cottone M, Criscuoli V. Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol 2011;4:227-38. [PMID: 22016584 DOI: 10.2147/CEG.S6440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
79 Afif W, Loftus EV. Safety Profile of IBD Therapeutics: Infectious Risks. Gastroenterology Clinics of North America 2009;38:691-709. [DOI: 10.1016/j.gtc.2009.07.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
80 Trivedi I, Hanauer SB. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf 2015;14:1915-34. [PMID: 26559664 DOI: 10.1517/14740338.2015.1108961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
81 Fefferman DS, Farrell RJ. Immunogenicity of biological agents in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:497-503. [PMID: 15867590 DOI: 10.1097/01.mib.0000161536.97412.41] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
82 Falconer H, Mwenda J, Chai D, Wagner C, Song X, Mihalyi A, Simsa P, Kyama C, Cornillie F, Bergqvist A, Fried G, D’hooghe T. Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon. Human Reproduction 2006;21:1856-62. [DOI: 10.1093/humrep/del044] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 4.6] [Reference Citation Analysis]
83 Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004;10:657-660. [PMID: 15472531 DOI: 10.1097/00054725-200409000-00025] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
84 Ljung T, Thomsen OØ, Vatn M, Karlén P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Löfberg R. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007;42:221-7. [PMID: 17327942 DOI: 10.1080/00365520600979369] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
85 Zhen Y, Liao L, Zhang H. Intestinal Giardiasis Disguised as Ulcerative Colitis. Case Rep Gastrointest Med 2018;2018:8968976. [PMID: 29854495 DOI: 10.1155/2018/8968976] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Gonzaga JE, Ananthakrishnan AN, Issa M, Beaulieu DB, Skaros S, Zadvornova Y, Johnson K, Otterson MF, Binion DG. Durability of infliximab in Crohn's disease: a single-center experience. Inflamm Bowel Dis. 2009;15:1837-1843. [PMID: 19462426 DOI: 10.1002/ibd.20974] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
87 Shivaji UN, Sharratt CL, Thomas T, Smith SCL, Iacucci M, Moran GW, Ghosh S, Bhala N. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:664-80. [DOI: 10.1111/apt.15097] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
88 Fréling E, Baumann C, Cuny J, Bigard M, Schmutz J, Barbaud A, Peyrin-biroulet L. Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience. American Journal of Gastroenterology 2015;110:1186-96. [DOI: 10.1038/ajg.2015.205] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 10.3] [Reference Citation Analysis]
89 Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594. [PMID: 18242222 DOI: 10.1053/j.gastro.2007.11.059] [Cited by in Crossref: 1201] [Cited by in F6Publishing: 1136] [Article Influence: 85.8] [Reference Citation Analysis]
90 Teriaky A, Gregor J, Yan B, Ponich T, Chande N, Mosli M. The safety and efficacy of adalimumab in patients with Crohn's disease: the experience of a single Canadian tertiary care centre. Scandinavian Journal of Gastroenterology 2013;49:280-6. [DOI: 10.3109/00365521.2013.865785] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
91 Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther 2005;22:1107-13. [PMID: 16305724 DOI: 10.1111/j.1365-2036.2005.02670.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
92 Lahad A, Weiss B. Current therapy of pediatric Crohn’s disease. World J Gastrointest Pathophysiol 2015; 6(2): 33-42 [PMID: 25977836 DOI: 10.4291/wjgp.v6.i2.33] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
93 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.8] [Reference Citation Analysis]
94 Ho GT, Mowat A, Potts L, Cahill A, Mowat C, Lees CW, Hare NC, Wilson JA, Boulton-jones R, Priest M, Watts DA, Shand AG, Arnott ID, Russell RK, Wilson DC, Morris AJ, Satsangi J. Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004-2008). Alimentary Pharmacology & Therapeutics 2009;29:527-34. [DOI: 10.1111/j.1365-2036.2008.03919.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
95 Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005;8:187-196. [PMID: 15913508 DOI: 10.1007/s11938-005-0011-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
96 Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009;84:979-84. [PMID: 19880688 DOI: 10.4065/84.11.979] [Cited by in Crossref: 12] [Cited by in F6Publishing: 34] [Article Influence: 0.9] [Reference Citation Analysis]
97 Kalman RS, Hartshorn K, Farraye FA. Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD. Inflamm Bowel Dis 2015;21:428-35. [PMID: 25251059 DOI: 10.1097/MIB.0000000000000211] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
98 Scheiba N, Hartschuh W. [Perianal streptococcal dermatitis caused by β-hemolytic group G streptococci in two adults]. Hautarzt 2011;62:131-3. [PMID: 20835811 DOI: 10.1007/s00105-010-1977-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
99 Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166-182. [PMID: 17893983 DOI: 10.1196/annals.1422.019] [Cited by in Crossref: 117] [Cited by in F6Publishing: 84] [Article Influence: 7.8] [Reference Citation Analysis]
100 Mir Subías A, García-López S, Sebastián Torres B, Ollero Domenche L, García Gámez A, Gomollón F. [Multiple sclerosis as an adverse effect of anti-tumor necrosis factor agents: an infrequent but important complication of infliximab in Crohn's disease]. Gastroenterol Hepatol 2013;36:81-5. [PMID: 23218770 DOI: 10.1016/j.gastrohep.2012.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
101 Witth�ft T, Ludwig D. Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn?s disease: a retrospective data analysis in Germany. Int J Colorectal Dis 2005;20:18-23. [DOI: 10.1007/s00384-004-0645-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
102 Segarra Cantón O, Infante Pina D, Tormo Carnicé R. [Infliximab therapy for inflammatory bowel disease: seven years on]. An Pediatr (Barc) 2007;67:344-51. [PMID: 17949644 DOI: 10.1016/s1695-4033(07)70652-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Soh JS, Yun WJ, Kim K, Won CH, Park SH, Yang D, Ye BD, Byeon J, Myung S, Yang S, Kim J. Concomitant Use of Azathioprine/6-Mercaptopurine Decreases the Risk of Anti-TNF–Induced Skin Lesions: . Inflammatory Bowel Diseases 2015;21:832-9. [DOI: 10.1097/mib.0000000000000342] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
104 Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Rev Gastroenterol Hepatol 2007;4:78-91. [DOI: 10.1038/ncpgasthep0695] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
105 Marks LR, Dodd H, Russo TA, Berenson CS. Burkholderia ginsengisoli bacteraemia: emergence of a novel pathogen. BMJ Case Rep 2016;2016:bcr2015213584. [PMID: 26912763 DOI: 10.1136/bcr-2015-213584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
106 Ferreira F, Lopes S, Macedo G. Colon cancer after infliximab therapy for Crohn's disease. BioDrugs 2010;24 Suppl 1:18-21. [PMID: 21175230 DOI: 10.2165/11586280-000000000-00000] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
107 Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV. Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study. Inflammatory Bowel Diseases 2013;19:1384-9. [DOI: 10.1097/mib.0b013e318281325e] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
108 Stansfield C. Risk assessment for new therapies in inflammatory bowel disease. Nurse Prescribing 2010;8:551-5. [DOI: 10.12968/npre.2010.8.11.79791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Fonseca A, Sunny J, Felipez LM. Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn's Disease. Case Rep Pediatr 2021;2021:9989729. [PMID: 34336341 DOI: 10.1155/2021/9989729] [Reference Citation Analysis]
110 Edwards D, Boritz E, Cowen EW, Brown RS. Erythema multiforme major following treatment with infliximab. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115:e36-e40. [PMID: 23036796 DOI: 10.1016/j.oooo.2012.08.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
111 Lu C, Waugh A, Bailey RJ, Cherry R, Dieleman LA, Gramlich L, Matic K, Millan M, Kroeker KI, Sadowski D, Teshima CW, Todoruk D, Wong C, Wong K, Fedorak RN. Crohn’s disease genotypes of patients in remission vs relapses after infliximab discontinuation. World J Gastroenterol 2012; 18(36): 5058-5064 [PMID: 23049214 DOI: 10.3748/wjg.v18.i36.5058] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
112 Sartor RB, Mazmanian SK. Intestinal Microbes in Inflammatory Bowel Diseases. Am J Gastroenterol Suppl 2012;1:15-21. [DOI: 10.1038/ajgsup.2012.4] [Cited by in Crossref: 142] [Cited by in F6Publishing: 59] [Article Influence: 14.2] [Reference Citation Analysis]
113 Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008;10:202. [PMID: 18226185 DOI: 10.1186/ar2341] [Cited by in Crossref: 105] [Cited by in F6Publishing: 95] [Article Influence: 7.5] [Reference Citation Analysis]
114 Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol. 2007;102:2058-2069. [PMID: 17561966 DOI: 10.1111/j.1572-0241.2007.01343.x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 152] [Article Influence: 9.8] [Reference Citation Analysis]
115 Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, Papa G, Gasbarrini A. Biological therapies for inflammatory bowel disease: controversies and future options. Expert Rev Clin Pharmacol. 2009;2:391-403. [PMID: 22112183 DOI: 10.1586/ecp.09.12] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
116 Tremaine WJ, Timmons LJ, Loftus EV, Pardi DS, Sandborn WJ, Harmsen WS, Thapa P, Zinsmeister AR. Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease: AGE AT ONSET OF IBD AND RISK OF SURGERY. Alimentary Pharmacology & Therapeutics 2007;25:1435-41. [DOI: 10.1111/j.1365-2036.2007.03341.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
117 Gomollón F. Seguridad de los tratamientos en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2006;29:45-51. [DOI: 10.1157/13098294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
119 Ruocco E, Cuomo A, Salerno R, Ruocco V, Romano M, Baroni A. Crohn’s disease and its mucocutaneous involvement. Skinmed. 2007;6:179-185. [PMID: 17618178 DOI: 10.1111/j.1540-9740.2007.05907.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
120 Wu GJ, Gong L, Xu M, Zhu YW. Infliximab combined with enteral nutrition for management of moderate to severe Crohn's disease. Shijie Huaren Xiaohua Zazhi 2013; 21(22): 2221-2227 [DOI: 10.11569/wcjd.v21.i22.2221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Stobaugh DJ, Deepak P, Ehrenpreis ED. Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. Clin Exp Gastroenterol. 2013;6:43-49. [PMID: 23818801 DOI: 10.2147/ceg.s42514] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
122 Rahier JF. Prevention and management of infectious complications in IBD. Dig Dis. 2012;30:408-414. [PMID: 22796807 DOI: 10.1159/000338143] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
123 Eisendle K, Fritsch P. Fatal fulminant legionnaires' disease in a patient with severe erythodermic psoriasis treated with infliximab after long-term steroid therapy. Br J Dermatol 2005;152:585-6. [DOI: 10.1111/j.1365-2133.2005.06431.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
124 Tookman AJ, Jones CL, DeWitte M, Lodge PJ. Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab. Support Care Cancer 2008;16:1131-40. [PMID: 18493801 DOI: 10.1007/s00520-008-0429-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
125 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
126 Griffiths AM. Enteral nutrition in the management of Crohn’s disease. JPEN J Parenter Enteral Nutr. 2005;29:S108-S12; discussion S108-S112; discussion S112-7, S184-8. [PMID: 15980272 DOI: 10.1177/01486071050290s4s108] [Cited by in Crossref: 34] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
127 Cottone M, Mocciaro F, Modesto I. Infliximab and ulcerative colitis. Expert Opinion on Biological Therapy 2006;6:401-8. [DOI: 10.1517/14712598.6.4.401] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
128 Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004;20:1347-1352. [PMID: 15606397 DOI: 10.1111/j.1365-2036.2004.02288.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 5.4] [Reference Citation Analysis]
129 Su C, Lichtenstein GR. Are there predictors of Remicade treatment success or failure? Adv Drug Deliv Rev. 2005;57:237-245. [PMID: 15555740 DOI: 10.1016/j.addr.2004.08.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
130 Chow DK, Leong RW. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opinion on Drug Safety 2007;6:479-85. [DOI: 10.1517/14740338.6.5.479] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
131 Devasahayam J, Pillai U, Lacasse A. A rare case of pericarditis, complication of infliximab treatment for Crohn's disease.J Crohns Colitis. 2012;6:730-731. [PMID: 22465046 DOI: 10.1016/j.crohns.2012.02.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
132 Domènech E, Esteve M, Gomollón F, Hinojosa J, Panés J, Obrador A, Gassull M. Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2005;28:126-34. [DOI: 10.1157/13072012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
133 Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn’s disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother. 2007;61:75-80. [PMID: 17184965 DOI: 10.1016/j.biopha.2006.06.022] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
134 Lightner AL, Mckenna NP, Tse CS, Raffals LE, Loftus EV, Mathis KL. Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations. Aliment Pharmacol Ther 2018;47:573-80. [DOI: 10.1111/apt.14459] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
135 Krane MK, Allaix ME, Zoccali M, Umanskiy K, Rubin MA, Villa A, Hurst RD, Fichera A. Preoperative Infliximab Therapy Does Not Increase Morbidity and Mortality After Laparoscopic Resection for Inflammatory Bowel Disease. Diseases of the Colon & Rectum 2013;56:449-57. [DOI: 10.1097/dcr.0b013e3182759029] [Cited by in Crossref: 47] [Cited by in F6Publishing: 11] [Article Influence: 5.2] [Reference Citation Analysis]
136 Marques M, Magro F, Cardoso H, Carneiro F, Portugal R, Lopes J, Costa Santos C. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis. 2008;14:723-725. [PMID: 17929297 DOI: 10.1002/ibd.20293] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
137 Hata T, Kavanaugh A. Rheumatoid arthritis in dermatology. Clin Dermatol 2006;24:430-7. [PMID: 16966022 DOI: 10.1016/j.clindermatol.2006.07.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
138 Ye BD. [Inflammatory bowel disease and lymphoproliferative disorders]. Korean J Gastroenterol 2011;58:171-7. [PMID: 22042416 DOI: 10.4166/kjg.2011.58.4.171] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
139 Davies SC, Nguyen TM, Parker CE, MacDonald JK, Jairath V, Khanna R. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.Cochrane Database Syst Rev. 2019;12:CD012804. [PMID: 31828765 DOI: 10.1002/14651858.CD012804.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
140 Ancowitz B, Shah SA. Infusion services in the gastroenterology practice. Gastrointest Endosc Clin N Am 2006;16:727-42. [PMID: 17098619 DOI: 10.1016/j.giec.2006.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
141 Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56:1125-1133. [PMID: 17393394 DOI: 10.1002/art.22504] [Cited by in Crossref: 268] [Cited by in F6Publishing: 208] [Article Influence: 17.9] [Reference Citation Analysis]
142 Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS. Infliximab improves inflammation and anthropometric measures in pediatric Crohn’s disease. J Gastroenterol Hepatol. 2010;25:810-816. [PMID: 20492339 DOI: 10.1111/j.1440-1746.2009.06195.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
143 Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol. 2007;42:16-25. [PMID: 17322989 DOI: 10.1007/s00535-006-1995-7] [Cited by in Crossref: 160] [Cited by in F6Publishing: 155] [Article Influence: 10.7] [Reference Citation Analysis]
144 Grimpen F, Pavli P. Advances in the management of inflammatory bowel disease. Intern Med J 2010;40:258-64. [PMID: 20059603 DOI: 10.1111/j.1445-5994.2010.02163.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
145 Aspinall AI, Adams DH. Sickness behaviors in chronic cholestasis: An immune-mediated process? Hepatology 2006;43:20-3. [DOI: 10.1002/hep.21032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
146 Blackmore L, Harris A. A prospective study of infliximab withdrawal after 12 months of treatment in patients with Crohn's disease: how will NICE guidance affect patient care? Clin Med (Lond) 2012;12:235-8. [PMID: 22783774 DOI: 10.7861/clinmedicine.12-3-235] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
147 Katz J, Frank M. Prolonged fever after Infliximab infusion. World J Gastrointest Pharmacol Ther 2012; 3(3): 34-35 [PMID: 22966481 DOI: 10.4292/wjgpt.v3.i3.34] [Cited by in CrossRef: 2] [Article Influence: 0.2] [Reference Citation Analysis]
148 Choi SJ, Ahn SM, Oh JS, Hong S, Lee CK, Yoo B, Ye BD, Yang SK, Park SH, Kim YG. Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea. Therap Adv Gastroenterol 2021;14:1756284821997794. [PMID: 33747126 DOI: 10.1177/1756284821997794] [Reference Citation Analysis]
149 Mosli MH, Feagan BG. Vedolizumab for Crohn’s disease. Expert Opin Biol Ther. 2013;13:455-463. [PMID: 23394379 DOI: 10.1517/14712598.2013.770835] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
150 Cohen BL, Torres J, Colombel JF. Immunosuppression in inflammatory bowel disease: how much is too much? Curr Opin Gastroenterol 2012;28:341-8. [PMID: 22573191 DOI: 10.1097/MOG.0b013e328354567f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
151 Schluender SJ, Ippoliti A, Dubinsky M, Vasiliauskas EA, Papadakis KA, Mei L, Targan SR, Fleshner PR. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007;50:1747-1753. [PMID: 17704969 DOI: 10.1007/s10350-007-9008-3] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 6.9] [Reference Citation Analysis]
152 Lioté H. Complications respiratoires des nouveaux traitements de la maladie rhumatoïde. Revue des Maladies Respiratoires 2004;21:1107-15. [DOI: 10.1016/s0761-8425(04)71585-5] [Cited by in Crossref: 32] [Article Influence: 1.8] [Reference Citation Analysis]
153 Feuerstein JD, Cullen G, Cheifetz AS. Immune-mediated Reactions to Anti-tumor Necrosis Factors in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2015;21:1176-86. [DOI: 10.1097/mib.0000000000000279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
154 Marie I, Guglielmino E. [Non tuberculous anti-TNF associated opportunistic infections]. Rev Med Interne 2010;31:353-60. [PMID: 20381217 DOI: 10.1016/j.revmed.2009.04.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
155 Sorrentino D, Avellini C, Beltrami CA, Pasqual E, Zearo E. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis 2006;21:276-81. [PMID: 15951989 DOI: 10.1007/s00384-005-0739-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
156 Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Alimentary Pharmacology & Therapeutics 2009;30:253-64. [DOI: 10.1111/j.1365-2036.2009.04037.x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 131] [Article Influence: 10.8] [Reference Citation Analysis]
157 Segal JP, Htet HMT, Limdi J, Hayee B. How to manage IBD in the 'elderly'. Frontline Gastroenterol 2020;11:468-77. [PMID: 33101625 DOI: 10.1136/flgastro-2019-101218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
158 Nugent Z, Blanchard JF, Bernstein CN. A Population-Based Study of Health-Care Resource Use Among Infliximab Users. American Journal of Gastroenterology 2010;105:2009-16. [DOI: 10.1038/ajg.2010.139] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
159 Quispel R, van der Worp HB, Pruissen M, Schipper ME, Oldenburg B. Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease. Gut 2006;55:1056. [PMID: 16766769 DOI: 10.1136/gut.2006.093294] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
160 Everett SM, Hamlin PJ. Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011? Frontline Gastroenterol 2011;2:144-50. [PMID: 28839599 DOI: 10.1136/fg.2010.003566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
161 Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, Sands BE. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007;133:769-79. [PMID: 17628557 DOI: 10.1053/j.gastro.2007.04.075] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 8.8] [Reference Citation Analysis]
162 Herrlinger KR, Stange EF, Fellermann K. Therapeutic peptides in inflammatory bowel disease. Expert Opin Biol Ther 2014;14:455-66. [PMID: 24450849 DOI: 10.1517/14712598.2014.880109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
163 Pressman AR, Hutfless S, Velayos F, Fireman B, Lewis JD, Allison J, Abramson O, Herrinton LJ. Patterns of infliximab use among Crohn's disease patients in a community setting. Inflamm Bowel Dis 2008;14:1265-72. [PMID: 18452199 DOI: 10.1002/ibd.20483] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
164 Poupardin C, Lémann M, Gendre J, Sabaté J, Marteau P, Chaussade S, Delchier J, Bouhnik Y, Chaput J, Poupon R, Soulé J, Benhamou Y, Grangé J, Coffin B. Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroentérologie Clinique et Biologique 2006;30:247-52. [DOI: 10.1016/s0399-8320(06)73161-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
165 Cullen G, Keegan D, Mulcahy HE, O'donoghue DP. A 5-Year Prospective Observational Study of the Outcomes of International Treatment Guidelines for Crohn's Disease. Clinical Gastroenterology and Hepatology 2009;7:323-8. [DOI: 10.1016/j.cgh.2008.10.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
166 Domènech E, Zabana Y, Mañosa M, Garcia-planella E, Cabré E, Gassull MÀ. Infliximab Reintroduction is Not Associated to a Higher Rate of Immune-related Adverse Effects in Patients With Inflammatory Bowel Disease Initially Treated With a Three-infusion Induction Regimen. Journal of Clinical Gastroenterology 2010;44:34-7. [DOI: 10.1097/mcg.0b013e3181962dfa] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
167 Bewtra M, Johnson FR. Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient 2013;6:241-55. [PMID: 24127239 DOI: 10.1007/s40271-013-0031-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
168 Kierkuś J, Iwańczak B, Wegner A, Dadalski M, Grzybowska-Chlebowczyk U, Łazowska I, Maślana J, Toporowska-Kowalska E, Czaja-Bulsa G, Mierzwa G, Korczowski B, Czkwianianc E, Żabka A, Szymańska E, Krzesiek E, Więcek S, Sładek M. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease. J Pediatr Gastroenterol Nutr 2015;60:580-5. [PMID: 25564804 DOI: 10.1097/MPG.0000000000000684] [Cited by in Crossref: 37] [Cited by in F6Publishing: 9] [Article Influence: 6.2] [Reference Citation Analysis]
169 Sturm A, Maaser C, Mendall M, Karagiannis D, Karatzas P, Ipenburg N, Sebastian S, Rizzello F, Limdi J, Katsanos K, Schmidt C, Jeuring S, Colombo F, Gionchetti P. European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly. J Crohns Colitis 2017;11:263-73. [PMID: 27797918 DOI: 10.1093/ecco-jcc/jjw188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
170 Siddiki H, Fletcher JG, Hara AK, Kofler JM, McCollough CH, Fidler JL, Guimaraes L, Huprich JE, Sandborn WJ, Loftus EV. Validation of a lower radiation computed tomography enterography imaging protocol to detect Crohn’s disease in the small bowel. Inflamm Bowel Dis. 2011;17:778-786. [PMID: 20848546 DOI: 10.1002/ibd.21364] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
171 Myśliwiec M, Balcerska A, Zorena K, Myśliwska J, Wiśniewski P. Immunologic and Biochemical Factors of Coincident Celiac Disease and Type 1 Diabetes Mellitus in Children. Pediatr Res 2008;64:677-81. [DOI: 10.1203/pdr.0b013e318187189e] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
172 Beaugerie L, Pardi DS. Patients With Drug-Induced Microscopic Colitis Should Not Be Included in Controlled Trials Assessing the Efficacy of Anti-Inflammatory Drugs in Microscopic Colitis. Gastroenterology 2009;137:1535-6. [DOI: 10.1053/j.gastro.2009.04.067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
173 Thielen A, Kuenzli S, Saurat J. Cutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the Literature. Dermatology 2005;211:209-17. [DOI: 10.1159/000087013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
174 Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
175 Parisian KR, Lopez R, Shen B. Chronic Pouch Inflammation and Risk for New-Onset Extraintestinal Cancers in Patients With Restorative Proctocolectomy for Ulcerative Colitis: . Inflammatory Bowel Diseases 2013;19:806-11. [DOI: 10.1097/mib.0b013e31827feba5] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
176 Dziki A, Galbfach P. Crohn's disease--when to operate? Acta Chir Iugosl 2004;51:61-8. [PMID: 15771291 DOI: 10.2298/aci0402061d] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
177 Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Medvedeva E, Xie D, Yang YX. Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients. Inflamm Bowel Dis 2021:izab163. [PMID: 34245261 DOI: 10.1093/ibd/izab163] [Reference Citation Analysis]
178 Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, Dong SH, Kim HJ, Kim BH, Chang YW. [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience]. Korean J Gastroenterol 2013;61:270-8. [PMID: 23756669 DOI: 10.4166/kjg.2013.61.5.270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
179 Thillard EM, Gautier S, Babykina E, Carton L, Amad A, Bouzillé G, Beuscart JB, Ficheur G, Chazard E. Psychiatric Adverse Events Associated With Infliximab: A Cohort Study From the French Nationwide Discharge Abstract Database. Front Pharmacol 2020;11:513. [PMID: 32390850 DOI: 10.3389/fphar.2020.00513] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
180 Vultaggio A, Nencini F, Pratesi S, Petroni G, Maggi E, Matucci A. Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. J Interferon Cytokine Res 2014;34:946-52. [PMID: 25493962 DOI: 10.1089/jir.2012.0139] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
181 Seiderer J, Göke B, Ochsenkühn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Digestion. 2004;70:3-9. [PMID: 15297773 DOI: 10.1159/000080075] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
182 Reenaers C, Pirard C, Vankemseke C, Latour P, Belaiche J, Louis E. Long-term evolution and predictive factors of mild inflammatory bowel disease. Scand J Gastroenterol 2016;51:712-9. [PMID: 26815198 DOI: 10.3109/00365521.2015.1128965] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
183 Eugène C. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease. Clinics and Research in Hepatology and Gastroenterology 2011;35:340-3. [DOI: 10.1016/j.clinre.2011.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
184 Yoshimura N, Yokoyama Y, Matsuoka K, Takahashi H, Iwakiri R, Yamamoto T, Nakagawa T, Fukuchi T, Motoya S, Kunisaki R, Kato S, Hirai F, Ishiguro Y, Tanida S, Hiraoka S, Mitsuyama K, Ishihara S, Tanaka S, Otaka M, Osada T, Kagaya T, Suzuki Y, Nakase H, Hanai H, Watanabe K, Kashiwagi N, Hibi T. An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. BMC Gastroenterol. 2015;15:163. [PMID: 26585569 DOI: 10.1186/s12876-015-0390-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
185 Bewtra M. Lymphoma in Inflammatory Bowel Disease and Treatment Decisions. American Journal of Gastroenterology 2012;107:964-70. [DOI: 10.1038/ajg.2011.479] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
186 Hagen JW, Magro CM, Crowson AN. Emerging Adverse Cutaneous Drug Reactions. Dermatologic Clinics 2012;30:695-730. [DOI: 10.1016/j.det.2012.06.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
187 Veres G, Baldassano RN, Mamula P. Infliximab therapy for pediatric Crohn's disease. Expert Opinion on Biological Therapy 2007;7:1869-80. [DOI: 10.1517/14712598.7.12.1869] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
188 Cummings JR, Jewell DP. Clinical implications of inflammatory bowel disease genetics on phenotype. Inflamm Bowel Dis. 2005;11:56-61. [PMID: 15674114 DOI: 10.1097/00054725-200501000-00008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
189 Guerin M, Haettich B, Bara C, Artru L, Prophette B, Célérier P, Maillard H. Lupus attributable to anti-TNF therapy and revealed by interstitial granulomatous dermatitis. Rheumatol Int 2012;32:2937-40. [PMID: 21800115 DOI: 10.1007/s00296-011-2016-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
190 Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:357-70. [DOI: 10.1586/17474124.2.3.357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
191 Lelong J, Duburque C, Fournier C, Colombel J, Desreumaux P, Tonnel A, Wallaert B. Accoutumance médicamenteuse à l’infliximab dans la maladie de Crohn. Revue des Maladies Respiratoires 2005;22:239-46. [DOI: 10.1016/s0761-8425(05)85477-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
192 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
193 Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis. 2015;9:806-815. [PMID: 26092578 DOI: 10.1093/ecco-jcc/jjv096] [Cited by in Crossref: 97] [Cited by in F6Publishing: 72] [Article Influence: 13.9] [Reference Citation Analysis]
194 Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J Pediatr Gastroenterol Nutr 2005;40:262-72. [PMID: 15735477 DOI: 10.1097/01.mpg.0000154660.62359.fe] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
195 Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. Journal of Dermatological Treatment 2009;15:280-94. [DOI: 10.1080/09546630410017275] [Cited by in Crossref: 217] [Cited by in F6Publishing: 186] [Article Influence: 16.7] [Reference Citation Analysis]
196 Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005;25:1181-92. [PMID: 16164393 DOI: 10.1592/phco.2005.25.9.1181] [Cited by in Crossref: 93] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
197 Mériglier E, Coudroy R, Agius G. Hépatite fulminante fatale à virus de la varicelle-zona chez une patiente porteuse d’une maladie de Crohn traitée par anti-TNF alpha. Médecine et Maladies Infectieuses 2014;44:484-6. [DOI: 10.1016/j.medmal.2014.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
198 Paterson GK, Orihuela CJ. Pneumococci: immunology of the innate host response. Respirology 2010;15:1057-63. [PMID: 20646240 DOI: 10.1111/j.1440-1843.2010.01814.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
199 Siddiki H, Fidler J. MR imaging of the small bowel in Crohn's disease. Eur J Radiol 2009;69:409-17. [PMID: 19118967 DOI: 10.1016/j.ejrad.2008.11.013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
200 Matsueda K, Toyokawa T, Sakata M, Fujita I, Horii J. Large Bowel Progressive Stricture after Infliximab Therapy for Crohn's Disease. Intern Med 2018;57:2179-83. [PMID: 29526964 DOI: 10.2169/internalmedicine.0583-17] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
201 Slattery E, Keegan D, O'Donoghue D. Anorectal stenosis after treatment with tumor necrosis factor alpha antibodies: a case series. J Med Case Rep 2010;4:226. [PMID: 20659338 DOI: 10.1186/1752-1947-4-226] [Reference Citation Analysis]
202 Pittet LF, Verolet CM, Michetti P, Girardin M, Juillerat P, Mottet C, Maillard MH, Siegrist C, Posfay-barbe KM; the Swiss Inflammatory Bowel Disease Cohort Study Group. High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease. Am J Gastroenterol 2019;114:1130-41. [DOI: 10.14309/ajg.0000000000000289] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
203 Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn WJ, Travis SP, Colombel JF. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011;106:1594-602; quiz 1593, 1603. [PMID: 21844919 DOI: 10.1038/ajg.2011.211] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
204 Pérez-de-lis M, Retamozo S, Flores-chávez A, Kostov B, Perez-alvarez R, Brito-zerón P, Ramos-casals M. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opinion on Drug Safety 2017;16:1255-71. [DOI: 10.1080/14740338.2017.1372421] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
205 Pearce CB, Lawrance IC. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J Gastroenterol Hepatol. 2007;22:1671-1677. [PMID: 17845695 DOI: 10.1111/j.1440-1746.2006.04739.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
206 Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of Life After Proctocolectomy With Ileoanal Anastomosis for Patients With Ulcerative Colitis: . Journal of Clinical Gastroenterology 2006;40:669-77. [DOI: 10.1097/00004836-200609000-00002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
207 Cosnes J, Seksik P. Maladies inflammatoires chroniques de l’intestin : de la sulfasalazine aux biothérapies. Gastroentérologie Clinique et Biologique 2009;33:692-701. [DOI: 10.1016/j.gcb.2009.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
208 Sobkeng Goufack E, Mammou S, Scotto B, De Muret A, Maakaroun A, Socie G, Bacq Y. Thrombose des veines hépatiques au cours d’un traitement par infliximab (Remicade®) révélant une hémoglobinurie paroxystique nocturne. Gastroentérologie Clinique et Biologique 2004;28:596-9. [DOI: 10.1016/s0399-8320(04)95017-8] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
209 Eliadou E, Moleiro J, Ribaldone DG, Astegiano M, Rothfuss K, Taxonera C, Ghalim F, Carbonnel F, Verstockt B, Festa S, Maia L, Berrozpe A, Zagorowicz E, Savarino E, Ellul P, Vavricka SR, Calvo M, Koutroubakis I, Hoentjen F, Salazar LF, Callela F, Cañete Pizarro F, Soufleris K, Sonnenberg E, Cavicchi M, Wypych J, Hommel C, Ghiani A, Fiorino G; ECCO CONFER COMMITTEE. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. Journal of Crohn's and Colitis 2020;14:480-9. [DOI: 10.1093/ecco-jcc/jjz165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
210 Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 2010;3:49-56. [PMID: 19794409 DOI: 10.1038/mi.2009.116] [Cited by in Crossref: 156] [Cited by in F6Publishing: 142] [Article Influence: 12.0] [Reference Citation Analysis]
211 Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn's Consensus Group. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202. [PMID: 19319383 DOI: 10.1155/2009/201430] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
212 Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2392-2403. [PMID: 22434654 DOI: 10.1002/ibd.22950] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
213 Reddy JG, Loftus EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006;35:837-855. [PMID: 17129816 DOI: 10.1016/j.gtc.2006.09.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
214 Efron JE, Young-Fadok TM. Preoperative optimization of Crohn's disease. Clin Colon Rectal Surg 2007;20:303-8. [PMID: 20011426 DOI: 10.1055/s-2007-991029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
215 Teitelbaum JE, Saeed S, Triantafyllopoulou M, Daum F. Infliximab in Pediatric Crohn Disease Patients With Enterovesicular Fistulas. Journal of Pediatric Gastroenterology & Nutrition 2007;44:279-82. [DOI: 10.1097/01.mpg.0000237933.38223.da] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
216 Leung VS, Nguyen MT, Bush TM. Disseminated primary varicella after initiation of infliximab for Crohn’s disease. Am J Gastroenterol. 2004;99:2503-2504. [PMID: 15571606 DOI: 10.1111/j.1572-0241.2004.41389_7.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 3.2] [Reference Citation Analysis]
217 Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15(17): 2067-2073 [PMID: 19418577 DOI: 10.3748/wjg.15.2067] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 67] [Article Influence: 5.3] [Reference Citation Analysis]
218 Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49:1837-1841. [PMID: 17041753 DOI: 10.1007/s10350-006-0656-5] [Cited by in Crossref: 126] [Cited by in F6Publishing: 95] [Article Influence: 8.4] [Reference Citation Analysis]
219 Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, Haslag S, Roberts CC. Safety of Infliximab Treatment in Pediatric Patients with Inflammatory Bowel Disease: . Journal of Pediatric Gastroenterology and Nutrition 2004;39:265-9. [DOI: 10.1097/00005176-200409000-00008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
220 Mascheretti S, Schreiber S. Genetic Testing in Crohn Disease: Utility in Individualizing Patient Management. American Journal of PharmacoGenomics 2005;5:213-22. [DOI: 10.2165/00129785-200505040-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
221 D'Arcangelo G, Distante M, Raso T, Rossetti D, Catassi G, Aloi M. Safety of Biological Therapy in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2021;72:736-41. [PMID: 33416268 DOI: 10.1097/MPG.0000000000003044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
222 D’Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol. 2010;7:86-92. [PMID: 20134490 DOI: 10.1038/nrgastro.2009.222] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
223 Shovman O, Tamar S, Amital H, Watad A, Shoenfeld Y. Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature. Clin Rheumatol 2018;37:563-8. [DOI: 10.1007/s10067-017-3884-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
224 Wang X, Cao J, Wang H, Ye C. Risk Factors Associated with Infusion Reactions to Infliximab in Chinese Patients with Inflammatory Bowel Disease: A Large Single-Center Study. Med Sci Monit 2019;25:2257-64. [PMID: 30917108 DOI: 10.12659/MSM.913152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
225 D'Haens G. Anti-TNF-alpha treatment strategies: results and clinical perspectives. Gastroenterol Clin Biol 2009;33 Suppl 3:S209-16. [PMID: 20117344 DOI: 10.1016/S0399-8320(09)73156-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
226 Melichar B, Bures J, Dedic K. Anorectal carcinoma after infliximab therapy in Crohn's disease: report of a case. Dis Colon Rectum. 2006;49:1228-1233. [PMID: 16845561 DOI: 10.1007/s10350-006-0647-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
227 Bewtra M, Lewis JD. Safety Profile of IBD: Lymphoma Risks. Medical Clinics of North America 2010;94:93-113. [DOI: 10.1016/j.mcna.2009.08.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
228 Ong MS, Grand RJ, Mandl KD. Trends in Pharmacologic Interventions for Preventing Recurrence of Crohn's Disease After Ileocolonic Surgery. Inflamm Bowel Dis 2016;22:2432-41. [PMID: 27631599 DOI: 10.1097/MIB.0000000000000898] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
229 Torres J, Cravo M, Colombel JF. Anti-TNF Withdrawal in Inflammatory Bowel Disease. GE Port J Gastroenterol 2016;23:153-61. [PMID: 28868451 DOI: 10.1016/j.jpge.2015.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
230 Šašala M, Majorová E, Vrzgula A, Fandáková I. Evaluation of Invasive Intra-abdominal Candidiasis in Crohn Disease at the Time of Surgery. Ann Coloproctol 2020;36:12-6. [PMID: 32146783 DOI: 10.3393/ac.2018.10.15.2] [Reference Citation Analysis]
231 Gisbert JP, Gomollón F. [Common errors in the management of the seriously ill patient with inflammatory bowel disease]. Gastroenterol Hepatol 2007;30:294-314. [PMID: 17493441 DOI: 10.1157/13101982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
232 Kwon JH, Farrell RJ. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Critical Reviews in Oncology/Hematology 2005;56:169-78. [DOI: 10.1016/j.critrevonc.2005.02.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
233 Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:51-58. [PMID: 21535447 DOI: 10.1111/j.1365-2036.2011.04682.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 9.9] [Reference Citation Analysis]
234 Orenstein R, Matteson EL. Opportunistic infections associated with TNF-α treatment. Future Rheumatology 2007;2:567-76. [DOI: 10.2217/17460816.2.6.567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
235 Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51. [PMID: 17632266 DOI: 10.1097/MD.0b013e3181441a68] [Cited by in Crossref: 476] [Cited by in F6Publishing: 121] [Article Influence: 31.7] [Reference Citation Analysis]
236 Ozkaraman A, Alparslan GB, Babadağ B, Kaşifoğlu T, Baydemir C. Effect of education and telephone counseling on adherence to treatment and challenges experienced in anti-TNF-α treatment: a pilot study. Contemporary Nurse 2018;54:108-19. [DOI: 10.1080/10376178.2017.1422776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
237 Lim CS, Moon W, Park SJ, Park MI, Kim HH, Kim JB, Choi JM, Chang HK, Lee SH. A rare case of free bowel perforation associated with infliximab treatment for stricturing Crohn’s disease. Korean J Gastroenterol. 2013;62:169-173. [PMID: 24077628 DOI: 10.4166/kjg.2013.62.3.169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
238 Taxonera C, Schwartz DA, García-Olmo D. Emerging treatments for complex perianal fistula in Crohn’s disease. World J Gastroenterol 2009; 15(34): 4263-4272 [PMID: 19750568 DOI: 10.3748/wjg.15.4263] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
239 Parihar V, Maguire S, Shahin A, Ahmed Z, O’sullivan M, Kennedy M, Smyth C, Farrell R. Listeria meningitis complicating a patient with ulcerative colitis on concomitant infliximab and hydrocortisone. Ir J Med Sci 2016;185:965-7. [DOI: 10.1007/s11845-015-1355-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
240 Soares SR, Martínez-varea A, Hidalgo-mora JJ, Pellicer A. Pharmacologic therapies in endometriosis: a systematic review. Fertility and Sterility 2012;98:529-55. [DOI: 10.1016/j.fertnstert.2012.07.1120] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 9.1] [Reference Citation Analysis]
241 Clark M, Colombel J, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006. Gastroenterology 2007;133:312-39. [DOI: 10.1053/j.gastro.2007.05.006] [Cited by in Crossref: 157] [Cited by in F6Publishing: 145] [Article Influence: 10.5] [Reference Citation Analysis]
242 Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn’s disease. Inflamm Bowel Dis. 2011;17:2366-2391. [PMID: 21337669 DOI: 10.1002/ibd.21655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
243 MacDonald JK, Nguyen TM, Khanna R, Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2016;11:CD007572. [PMID: 27885650 DOI: 10.1002/14651858.CD007572.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
244 Makanyanga JC, Taylor SA. Current and future role of MR enterography in the management of Crohn disease. AJR Am J Roentgenol. 2013;201:56-64. [PMID: 23789658 DOI: 10.2214/ajr.12.10406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
245 Stucchi A, Reed K, O’Brien M, Cerda S, Andrews C, Gower A, Bushell K, Amar S, Leeman S, Becker J. A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC. Inflamm Bowel Dis. 2006;12:581-587. [PMID: 16804395 DOI: 10.1097/01.mib.0000225338.14356.d5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
246 Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004;53:780-2. [PMID: 15138201 DOI: 10.1136/gut.2003.020552] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
247 Ruemmele FM. Infliximab: How to Use It in Pediatric Crohn’s Disease: . Journal of Pediatric Gastroenterology and Nutrition 2004;39:12-4. [DOI: 10.1097/00005176-200407000-00004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
248 Baars JE, Siegel CA, Kuipers EJ, van der Woude CJ. Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion 2009;79:30-5. [PMID: 19246918 DOI: 10.1159/000203638] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
249 D’haens G, Hlavaty T. Advances in medical therapy for Crohn’s disease. Curr Gastroenterol Rep 2004;6:496-505. [DOI: 10.1007/s11894-004-0072-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
250 Sartor RB, Hoentjen F. Proinflammatory Cytokines and Signaling Pathways in Intestinal Innate Immune Cells. Mucosal Immunology. Elsevier; 2005. pp. 681-701. [DOI: 10.1016/b978-012491543-5/50039-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
251 Ali T, Yun L, Rubin DT. Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol 2012; 18(3): 197-204 [PMID: 22294822 DOI: 10.3748/wjg.v18.i3.197] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
252 Duricova D, Pedersen N, Lenicek M, Hradsky O, Bronsky J, Adamcova M, Elkjaer M, Andersen PS, Vitek L, Larsen K, Lukas M, Nevoral J, Wewer V, Munkholm P. Infliximab dependency in children with Crohn’s disease. Alimentary Pharmacology & Therapeutics 2009;29:792-9. [DOI: 10.1111/j.1365-2036.2009.03926.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
253 Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors’ reply: Letters to the Editors. Alimentary Pharmacology & Therapeutics 2011;34:404-5. [DOI: 10.1111/j.1365-2036.2011.04748.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
254 Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflamm Bowel Dis 2018;24:2272-7. [PMID: 29718223 DOI: 10.1093/ibd/izy133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
255 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
256 Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, Margolis DJ, Strom BL. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1428-1435; quiz 1436. [PMID: 18494836 DOI: 10.1111/j.1572-0241.2008.01836.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 4.5] [Reference Citation Analysis]
257 Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010;9:325-38. [PMID: 20305665 DOI: 10.1038/nrd3003] [Cited by in Crossref: 551] [Cited by in F6Publishing: 477] [Article Influence: 45.9] [Reference Citation Analysis]
258 Bewtra M, Newcomb CW, Wu Q, Chen L, Xie F, Roy JA, Aarons CB, Osterman MT, Forde KA, Curtis JR, Lewis JD. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med 2015;163:262-70. [PMID: 26168366 DOI: 10.7326/M14-0960] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
259 Ochsenkühn T, Sackmann M, Göke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. European Journal of Gastroenterology & Hepatology 2004;16:1167-71. [DOI: 10.1097/00042737-200411000-00014] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 4.7] [Reference Citation Analysis]
260 Scheid R, Teich N. Neurologic manifestations of ulcerative colitis. Eur J Neurol 2007;14:483-93. [PMID: 17437605 DOI: 10.1111/j.1468-1331.2007.01718.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 4.0] [Reference Citation Analysis]
261 Limdi JK, Shaffer JL. How "NICE" were we with infliximab? Inflamm Bowel Dis 2005;11:705-6. [PMID: 15973126 DOI: 10.1097/01.mib.0000169733.88645.da] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
262 Casella G, Villanacci V, Di Bella C, Antonelli E, Baldini V, Bassotti G. Pulmonary diseases associated with inflammatory bowel diseases. J Crohns Colitis. 2010;4:384-389. [PMID: 21122533 DOI: 10.1016/j.crohns.2010.02.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
263 Hirche D, Rubbert A, Lunau L, Krieg T, Eming S. Successful treatment of refractory rheumatoid arthritis-associated leg ulcerations with adalimumab. Br J Dermatol 2005;152:1062-4. [DOI: 10.1111/j.1365-2133.2005.06520.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
264 Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Digestive and Liver Disease 2008;40:S236-46. [DOI: 10.1016/s1590-8658(08)60532-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
265 Karoui S, Bibani N, Gorbel IB, Serghini M, Mlika M, Braham A, Chelly I, Haouet S, Houmène H, Filali A. Leukocytoclastic vasculitis: A rare adverse effect secondary to infliximab. Inflammatory Bowel Diseases 2011;17:E4-5. [DOI: 10.1002/ibd.21309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
266 Lakatos L, Lakatos PL. [Medical therapy of inflammatory bowel diseases: Crohn's disease]. Orv Hetil 2007;148:1107-14. [PMID: 17561480 DOI: 10.1556/OH.2007.28062] [Reference Citation Analysis]
267 Bouguen G, Trouilloud I, Siproudhis L, Oussalah A, Bigard M, Bretagne J, Peyrin-biroulet L. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn’s disease in patients treated with infliximab. Alimentary Pharmacology & Therapeutics 2009;30:749-56. [DOI: 10.1111/j.1365-2036.2009.04089.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
268 De Witte M, Shealy DJ, Nakada MT, Anderson GM. Tumor Necrosis Factor and Cancer. In: Caligiuri MA, Lotze MT, editors. Cytokines in the Genesis and Treatment of Cancer. Totowa: Humana Press; 2007. pp. 71-89. [DOI: 10.1007/978-1-59745-455-1_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
269 Evans PE, Pardi DS. Inflammatory bowel disease in the elderly. Aging Health 2007;3:77-84. [DOI: 10.2217/1745509x.3.1.77] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
270 De Bie CI, Hummel TZ, Kindermann A, Kokke FT, Damen GM, Kneepkens CM, Van Rheenen PF, Schweizer JJ, Hoekstra JH, Norbruis OF, Tjon A Ten WE, Vreugdenhil AC, Deckers-Kocken JM, Gijsbers CF, Escher JC, De Ridder L. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Aliment Pharmacol Ther. 2011;33:243-250. [PMID: 21083595 DOI: 10.1111/j.1365-2036.2010.04507.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 4.3] [Reference Citation Analysis]
271 Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013;7:769-779. [PMID: 23453887 DOI: 10.1016/j.crohns.2013.01.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 7.4] [Reference Citation Analysis]
272 Dechant SA, Matteson EL. Managing Comorbidity Risks in Rheumatoid Arthritis: . Current Opinion in Rheumatology 2004;16:177-9. [DOI: 10.1097/00002281-200405000-00002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
273 Wei Q, Zhang X, Peng Y, Chen K, Xu S, Huang X, Zhang L, Xie Q, He Y, Li Y, Chai J. Successful treatment by thalidomide therapy of intestinal Behçet's disease associated with trisomy 8 myelodysplastic syndrome. Rheumatology (Oxford) 2021;60:e200-2. [PMID: 33331901 DOI: 10.1093/rheumatology/keaa848] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
274 Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benazzato L, Papi C, Meucci G, Riegler G, Petruzziello C, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006;55:228-33. [PMID: 16120759 DOI: 10.1136/gut.2005.075937] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
275 Kedia S, Limdi JK, Ahuja V. Management of inflammatory bowel disease in older persons: evolving paradigms. Intest Res 2018;16:194-208. [PMID: 29743832 DOI: 10.5217/ir.2018.16.2.194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
276 Seksik P, Cosnes J, Sokol H, Nion-Larmurier I, Gendre JP, Beaugerie L. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Aliment Pharmacol Ther. 2009;29:1106-1113. [PMID: 19222411 DOI: 10.1111/j.1365-2036.2009.03973.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
277 Ramírez-hernández M, Marras C, Martínez-escribano JA. Infliximab-Induced Vitiligo. Dermatology 2004;210:79-80. [DOI: 10.1159/000081494] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
278 Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, Masson P, De Keyser F. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 2010;49:1815-1827. [PMID: 20591834 DOI: 10.1093/rheumatology/keq183] [Cited by in Crossref: 137] [Cited by in F6Publishing: 105] [Article Influence: 11.4] [Reference Citation Analysis]
279 Van Assche G, Vermeire S, Rutgeerts P. Infliximab therapy for patients with inflammatory bowel disease: 10 years on. Eur J Pharmacol 2009;623 Suppl 1:S17-25. [PMID: 19837056 DOI: 10.1016/j.ejphar.2009.10.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
280 Wheat CL, Ko CW, Clark-Snustad K, Grembowski D, Thornton TA, Devine B. Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis. BMC Gastroenterol 2017;17:52. [PMID: 28407755 DOI: 10.1186/s12876-017-0602-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
281 Irving PM, Gibson PR. Infections and IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5:18-27. [PMID: 18174904 DOI: 10.1038/ncpgasthep1004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
282 Khanna R, Preiss JC, MacDonald JK, Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2015;:CD007572. [PMID: 25942580 DOI: 10.1002/14651858.CD007572.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
283 Beigel F, Jürgens M, Filik L, Bader L, Lück C, Göke B, Ochsenkühn T, Brand S, Seiderer J. Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohnʼs disease: . Inflammatory Bowel Diseases 2009;15:1240-4. [DOI: 10.1002/ibd.20866] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
284 Ben Musa R, Usha L, Hibbeln J, Mutlu EA. TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: A case report and literature review. World J Gastroenterol 2014; 20(19): 5912-5917 [PMID: 24914353 DOI: 10.3748/wjg.v20.i19.5912] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
285 Paulson EC. Biologic therapy and surgery for crohn disease. Clin Colon Rectal Surg 2013;26:128-34. [PMID: 24436661 DOI: 10.1055/s-0033-1348052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
286 Reguia?? Z, Grange F. The Role of Anti-Tumor Necrosis Factor-?? Therapy in Pyoderma Gangrenosum Associated with Inflammatory Bowel Disease: . American Journal of Clinical Dermatology 2007;8:67-77. [DOI: 10.2165/00128071-200708020-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
287 Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167-182. [PMID: 20227030 DOI: 10.1016/j.bpg.2010.01.002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 9.5] [Reference Citation Analysis]
288 Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1-16. [PMID: 15306569 DOI: 10.1136/gut.2004.04337253/suppl_5/v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
289 Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy 2015;35:412-23. [PMID: 25884529 DOI: 10.1002/phar.1561] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
290 Sorrentino D, Fogel S, Van den Bogaerde J. Surgery for Crohn’s disease and anti-TNF agents: the changing scenario. Expert Rev Gastroenterol Hepatol. 2013;7:689-700. [PMID: 24161133 DOI: 10.1586/17474124.2013.842895] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
291 Salvana EMT, Cooper GS, Salata RA. Mycobacterium other than tuberculosis (MOTT) infection: An emerging disease in infliximab-treated patients. Journal of Infection 2007;55:484-7. [DOI: 10.1016/j.jinf.2007.08.007] [Cited by in Crossref: 57] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
292 Jiang GL, Nieves A, Im WB, Old DW, Dinh DT, Wheeler L. The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther. 2007;320:22-28. [PMID: 17008451 DOI: 10.1124/jpet.106.111146] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 3.8] [Reference Citation Analysis]
293 Abdalla T, Lowes MA, Kaur N, Micheletti RG, Steinhart AH, Alavi A. Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors? Am J Clin Dermatol 2021;22:139-47. [PMID: 33398848 DOI: 10.1007/s40257-020-00579-z] [Reference Citation Analysis]
294 Bewtra M, Lewis JD. Safety profile of IBD: lymphoma risks. Gastroenterol Clin North Am 2009;38:669-89. [PMID: 19913208 DOI: 10.1016/j.gtc.2009.07.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
295 Kamm MA. Review article: biological drugs in Crohn's disease. Aliment Pharmacol Ther 2006;24:80-9. [DOI: 10.1111/j.1365-2036.2006.03066.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
296 Sprakes MB, Hamlin PJ. Anti-tumour necrosis factor-alpha therapies in Crohn's disease. Br J Hosp Med (Lond) 2009;70:644-7. [PMID: 20081592 DOI: 10.12968/hmed.2009.70.11.45055] [Reference Citation Analysis]
297 Siegel CA, Finlayson SR, Sands BE, Tosteson AN. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol 2012;10:46-51. [PMID: 21963958 DOI: 10.1016/j.cgh.2011.09.017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
298 Jones JL, Loftus EV. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis. 2007;13:1299-1307. [PMID: 17600819 DOI: 10.1002/ibd.20211] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 5.9] [Reference Citation Analysis]
299 Rojko JL, Evans MG, Price SA, Han B, Waine G, Dewitte M, Haynes J, Freimark B, Martin P, Raymond JT, Evering W, Rebelatto MC, Schenck E, Horvath C. Formation, Clearance, Deposition, Pathogenicity, and Identification of Biopharmaceutical-related Immune Complexes: Review and Case Studies. Toxicol Pathol 2014;42:725-64. [DOI: 10.1177/0192623314526475] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 11.0] [Reference Citation Analysis]
300 Roblin X, Oltean P, Heluwaert F, Bonaz B. Panic Attack with Suicide: An Exceptional Adverse Effect of Infliximab. Dig Dis Sci 2006;51:1056-1056. [DOI: 10.1007/s10620-006-8007-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
301 Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cézard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn’s disease. Clin Immunol. 2006;118:11-19. [PMID: 16125467 DOI: 10.1016/j.clim.2005.07.010] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 4.5] [Reference Citation Analysis]
302 Voss MH, Lunning MA, Maragulia JC, Papadopoulos EB, Goldberg J, Zelenetz AD, Horwitz SM. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 2013;13:8-14. [PMID: 23107915 DOI: 10.1016/j.clml.2012.09.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
303 Katsanos KH, Voulgari PV, Tsianos EV. Inflammatory bowel disease and lupus: a systematic review of the literature. J Crohns Colitis. 2012;6:735-742. [PMID: 22504032 DOI: 10.1016/j.crohns.2012.03.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
304 Bressler B, Sands BE. Review article: Medical therapy for fistulizing Crohn’s disease. Aliment Pharmacol Ther. 2006;24:1283-1293. [PMID: 17059510 DOI: 10.1111/j.1365-2036.2006.03126.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
305 Guthrie B, Rouster-stevens KA, Reynolds SL. Review of Medications Used in Juvenile Rheumatoid Arthritis: . Pediatric Emergency Care 2007;23:38-46. [DOI: 10.1097/pec.0b013e31802c61ae] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
306 Mulder DJ, Noble AJ, Justinich CJ, Duffin JM. A tale of two diseases: the history of inflammatory bowel disease. J Crohns Colitis. 2014;8:341-348. [PMID: 24094598 DOI: 10.1016/j.crohns.2013.09.009] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 7.9] [Reference Citation Analysis]
307 Carbone J, Gonzalez-Lara V, Sarmiento E, Chean C, Perez JL, Marin I, Rodríguez-Molina JJ, Gil J, Fernández-Cruz E. Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning treatment with infliximab. Ann N Y Acad Sci 2007;1107:346-55. [PMID: 17804562 DOI: 10.1196/annals.1381.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
308 Juillerat P, Pittet V, Felley C, Mottet C, Froehlich F, Vader JP, Gonvers JJ, Michetti P. Drug safety in Crohn's disease therapy. Digestion 2007;76:161-8. [PMID: 18239408 DOI: 10.1159/000111031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
309 Lavagna A, Bergallo M, Daperno M, Sostegni R, Costa C, Leto R, Crocellà L, Molinaro G, Rocca R, Cavallo R. Infliximab and the risk of latent viruses reactivation in active Crohn’s disease. Inflamm Bowel Dis. 2007;13:896-902. [PMID: 17345605 DOI: 10.1002/ibd.20131] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 4.9] [Reference Citation Analysis]
310 Williams G, Khan AA, Schweiger F. Listeria meningitis complicating infliximab treatment for Crohn's disease. Can J Infect Dis Med Microbiol 2005;16:289-92. [PMID: 18159561 DOI: 10.1155/2005/814698] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
311 Bermejo F, Algaba A, Chaparro M, Taxonera C, Garrido E, García-arata I, Guerra I, Gisbert JP, Olivares D, de-la-Poza G, López-sanromán A. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study. Digestive and Liver Disease 2013;45:733-7. [DOI: 10.1016/j.dld.2013.03.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
312 Biancone L, Petruzziello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci E, Castiglione F, D'Incà R, Zorzi F. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011;17:758-766. [PMID: 20684009 DOI: 10.1002/ibd.21416] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
313 Singh M, Diwan MM, Patel KC. A rare case of supraventricular tachycardia induced by Infliximab: a case report. Cases J. 2009;2:147. [PMID: 19946518 DOI: 10.1186/1757-1626-2-147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
314 Bourke SJ. Interstitial lung disease: progress and problems. Postgrad Med J 2006;82:494-9. [PMID: 16891438 DOI: 10.1136/pgmj.2006.046417] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
315 Méndez-García LA, Trejo-Millán F, Martínez-Reyes CP, Manjarrez-Reyna AN, Esquivel-Velázquez M, Melendez-Mier G, Islas-Andrade S, Rojas-Bernabé A, Kzhyshkowska J, Escobedo G. Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro. Scand J Immunol 2018;88:e12716. [PMID: 30260514 DOI: 10.1111/sji.12716] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
316 Baruah A, Kee Song LMW, Buttar NS. Endoscopic management of fistulas, perforations, and leaks. Techniques in Gastrointestinal Endoscopy 2015;17:178-88. [DOI: 10.1016/j.tgie.2016.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
317 Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201-211. [PMID: 21484965 DOI: 10.1002/ibd.21697] [Cited by in Crossref: 133] [Cited by in F6Publishing: 119] [Article Influence: 12.1] [Reference Citation Analysis]
318 Cohen-Mekelburg S, Waljee AK. Inflammatory Bowel Disease in the Older Adult. Clin Geriatr Med 2021;37:185-95. [PMID: 33213772 DOI: 10.1016/j.cger.2020.08.013] [Reference Citation Analysis]
319 Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006; 12(29): 4628-4635 [PMID: 16937430 DOI: 10.3748/wjg.v12.i29.4628] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
320 Chang J, Leong RW. Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure. Expert Opinion on Biological Therapy 2013;14:27-36. [DOI: 10.1517/14712598.2014.853738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
321 Ryan BM, Romberg M, Wolters F, Stockbrugger RW. Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction. Eur J Gastroenterol Hepatol. 2004;16:941-942. [PMID: 15316423 DOI: 10.1097/00042737-200409000-00022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
322 Enayati PJ, Papadakis KA. Association of Anti-tumor Necrosis Factor Therapy With the Development of Multiple Sclerosis. Journal of Clinical Gastroenterology 2005;39:303-6. [DOI: 10.1097/01.mcg.0000155126.82171.32] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
323 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
324 Margo F, Marques M, Costa Santos C. Episodic Infliximab treatment induces infusion reactions: . Inflammatory Bowel Diseases 2008;14:1608-10. [DOI: 10.1002/ibd.20476] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
325 Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2:731-743. [PMID: 15354273 DOI: 10.1016/s1542-3565(04)00344-1] [Cited by in Crossref: 145] [Cited by in F6Publishing: 42] [Article Influence: 8.1] [Reference Citation Analysis]
326 Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol. 2009;23:101-112. [PMID: 19258190 DOI: 10.1016/j.bpg.2008.12.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
327 Mill J, Lawrance IC. Preventing infective complications in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9691-9698 [PMID: 25110408 DOI: 10.3748/wjg.v20.i29.9691] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
328 Ducharme J, Pelletier C, Zacharias R. The safety of infliximab infusions in the community setting. Can J Gastroenterol 2010;24:307-11. [PMID: 20485705 DOI: 10.1155/2010/138456] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
329 Nagy G, Lukács K, Sziray Á, Fazekas K, Florián Á, Tamási L, Károlyi Z. Adverse events during biological therapy – focusing on dermatological side-effects. Orvosi Hetilap 2011;152:212-20. [DOI: 10.1556/oh.2011.28987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
330 Felley C, Michetti P. Safety of infliximab in patients suffering from inflammatory bowel disease. Digestion 2004;70:1-2. [PMID: 15297772 DOI: 10.1159/000080074] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
331 Legnani P, Kornbluth A. Newer therapies for inflammatory bowel disease. Curr Treat Options Gastro 2004;7:161-7. [DOI: 10.1007/s11938-004-0037-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
332 Baraliakos X, Braun J. Anti-TNF-α therapy with infliximab in spondyloarthritides. Expert Review of Clinical Immunology 2014;6:9-19. [DOI: 10.1586/eci.09.61] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
333 Casellas i Jordà F. [TNF-alpha inhibitors in inflammatory bowel disease]. Med Clin (Barc) 2004;123:627-34. [PMID: 15546523 DOI: 10.1016/s0025-7753(04)74622-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
334 Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: Results of a systematic review. World J Gastroenterol 2013; 19(27): 4344-4350 [PMID: 23885145 DOI: 10.3748/wjg.v19.i27.4344] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
335 Radin M, Sciascia S, Roccatello D, Cuadrado MJ. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. BioDrugs. 2017;31:37-49. [PMID: 28035633 DOI: 10.1007/s40259-016-0206-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 5.4] [Reference Citation Analysis]
336 Marth T. Systematic review: Whipple's disease ( Tropheryma whipplei infection) and its unmasking by tumour necrosis factor inhibitors. Aliment Pharmacol Ther 2015;41:709-24. [DOI: 10.1111/apt.13140] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
337 Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV, Sandborn WJ, Wolff BG, Pemberton JH. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204:956-962; discussion 962-963. [PMID: 17481518 DOI: 10.1016/j.jamcollsurg.2006.12.044] [Cited by in Crossref: 222] [Cited by in F6Publishing: 178] [Article Influence: 14.8] [Reference Citation Analysis]
338 Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, Gearry RB, Florin TH. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol. 2010;25:1732-1738. [PMID: 21039834 DOI: 10.1111/j.1440-1746.2010.06407.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
339 Egan LJ, Sandborn WJ. Positioning novel biologic, probiotic, and apheresis therapies for crohn’s disease and ulcerative colitis. Curr Gastroenterol Rep 2005;7:485-91. [DOI: 10.1007/s11894-005-0080-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
340 Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:221-33. [PMID: 16901386 DOI: 10.1007/s11938-006-0041-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
341 Sathish JG, Sethu S, Bielsky MC, de Haan L, French NS, Govindappa K, Green J, Griffiths CE, Holgate S, Jones D, Kimber I, Moggs J, Naisbitt DJ, Pirmohamed M, Reichmann G, Sims J, Subramanyam M, Todd MD, Van Der Laan JW, Weaver RJ, Park BK. Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov 2013;12:306-24. [PMID: 23535934 DOI: 10.1038/nrd3974] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 10.1] [Reference Citation Analysis]
342 Ordonez ME, Farraye FA, Di Palma JA. Endemic fungal infections in inflammatory bowel disease associated with anti-TNF antibody therapy. Inflamm Bowel Dis 2013;19:2490-500. [PMID: 23694943 DOI: 10.1097/MIB.0b013e31828f1fba] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
343 Chen Y, Shen Y, Ma HF, Cai JF, Hua YQ, Zou J, Guan JL. Infliximab associated with life-threatening lung infection in a patient with Behcet disease with intestinal and hematopoietic system involvement: A case report. Medicine (Baltimore) 2017;96:e9202. [PMID: 29390339 DOI: 10.1097/MD.0000000000009202] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
344 Bodger K. Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics 2005;23:875-88. [PMID: 16153132 DOI: 10.2165/00019053-200523090-00002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
345 Farkas K, Nagy F, Kovács L, Wittmann T, Molnár T. Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease--what is the role of anti-TNF antibody. J Crohns Colitis. 2013;7:e143-e145. [PMID: 22818164 DOI: 10.1016/j.crohns.2012.06.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
346 Faria R, Pereira C, Alves R, Mendonça T, Farinha F, Vasconcelos C. Opportunistic Infections and Autoimmune Diseases. Infection and Autoimmunity. Elsevier; 2015. pp. 251-77. [DOI: 10.1016/b978-0-444-63269-2.00018-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
347 Lee SJ, Kavanaugh A. Adverse reactions to biologic agents: focus on autoimmune disease therapies. J Allergy Clin Immunol. 2005;116:900-905. [PMID: 16210067 DOI: 10.1016/j.jaci.2005.03.028] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
348 Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol 2006;40:482-9. [PMID: 16825929 DOI: 10.1097/00004836-200607000-00005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
349 Yanai H, Shuster D, Calabrese E, Mlynarsky L, Tumuluri S, Cohen RD. The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies: . Inflammatory Bowel Diseases 2013;19:2778-86. [DOI: 10.1097/01.mib.0000435435.91988.b6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
350 Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, Morel P, Dubertret L, Bachelez H. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 2007;156:329-36. [PMID: 17223874 DOI: 10.1111/j.1365-2133.2006.07639.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
351 Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S. Predictive model for the outcome of infliximab therapy in Crohn’s disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis. 2007;13:372-379. [PMID: 17206723 DOI: 10.1002/ibd.20024] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
352 Bewtra M, Kilambi V, Fairchild AO, Siegel CA, Lewis JD, Johnson FR. Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis 2014;20:103-14. [PMID: 24280881 DOI: 10.1097/01.MIB.0000437498.14804.50] [Cited by in Crossref: 54] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
353 Nancey S, Blanvillain E, Parmentier B, Flourié B, Bayet C, Bienvenu J, Fabien N. Infliximab Treatment Does Not Induce Organ-specific or Nonorgan-specific Autoantibodies Other than Antinuclear and Anti-Double-Stranded DNA Autoantibodies in Crohnʼs Disease: . Inflammatory Bowel Diseases 2005;11:986-91. [DOI: 10.1097/01.mib.0000186408.07769.78] [Cited by in Crossref: 36] [Cited by in F6Publishing: 4] [Article Influence: 2.1] [Reference Citation Analysis]
354 Mcconachie SM, Wilhelm SM, Bhargava A, Kale-pradhan PB. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists. Ann Pharmacother 2018;52:571-9. [DOI: 10.1177/1060028018754896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
355 Siegel CA, Levy LC, Mackenzie TA, Sands BE. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1-6. [PMID: 17924559 DOI: 10.1002/ibd.20283] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
356 Condino G, Calabrese E, Zorzi F, Onali S, Lolli E, De Biasio F, Ascolani M, Pallone F, Biancone L. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study. Dig Liver Dis 2013;45:258-62. [PMID: 23195667 DOI: 10.1016/j.dld.2012.10.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
357 Chiorean MV, Pokhrel B, Adabala J, Helper DJ, Johnson CS, Juliar B. Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. Dig Dis Sci 2011;56:1489-95. [PMID: 20953706 DOI: 10.1007/s10620-010-1430-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
358 Boirivant M, Cossu A. Inflammatory bowel disease. Oral Dis. 2012;18:1-15. [PMID: 21564424 DOI: 10.1111/j.1601-0825.2011.01811.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
359 Lal S, Hillary Steinhart A. Infliximab for ulcerative colitis following liver transplantation: . European Journal of Gastroenterology & Hepatology 2007;19:277-80. [DOI: 10.1097/meg.0b013e3280116ccc] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
360 Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2009;54:269-278. [PMID: 19934608 DOI: 10.4166/kjg.2009.54.2.108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
361 Chang JT, Lichtenstein GR. Drug Insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2006;3:220-8. [DOI: 10.1038/ncpgasthep0447] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
362 Herrlinger KR, Fellermann K, Stange EF. Tacrolimus--finally! Gut 2006;55:1224-5. [PMID: 16905691 DOI: 10.1136/gut.2006.093302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
363 Poggioli G, Laureti S, Campieri M, Pierangeli F, Gionchetti P, Ugolini F, Gentilini L, Bazzi P, Rizzello F, Coscia M. Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag 2007;3:301-8. [PMID: 18360638 DOI: 10.2147/tcrm.2007.3.2.301] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
364 Uslu N, Usta Y, Saltik-Temizel IN, Demir H, Gürakan F, Ozen H, Yüce A. Ineffectiveness of infliximab therapy in severe infantile Crohn's disease. J Crohns Colitis 2010;4:106-9. [PMID: 21122492 DOI: 10.1016/j.crohns.2009.08.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
365 Veres G, Baldassano RN, Mamula P. Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease: . Drugs 2007;67:1703-23. [DOI: 10.2165/00003495-200767120-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
366 Kopylov U, Afif W. Risk of infections with biological agents. Gastroenterol Clin North Am 2014;43:509-24. [PMID: 25110256 DOI: 10.1016/j.gtc.2014.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
367 Flamant M, Bourreille A. Biothérapies et MICI: anti-TNF et nouvelles cibles thérapeutiques. La Revue de Médecine Interne 2007;28:852-61. [DOI: 10.1016/j.revmed.2007.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
368 Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881. [PMID: 19558997 DOI: 10.1016/j.cgh.2009.01.004] [Cited by in Crossref: 345] [Cited by in F6Publishing: 314] [Article Influence: 26.5] [Reference Citation Analysis]
369 Quezada SM, Mclean LP, Cross RK. Adverse events in IBD therapy: the 2018 update. Expert Review of Gastroenterology & Hepatology 2018;12:1183-91. [DOI: 10.1080/17474124.2018.1545574] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
370 Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr. 2007;96:128-130. [PMID: 17187619 DOI: 10.1111/j.1651-2227.2007.00042.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
371 Davis MR, Thompson GR 3rd, Patterson TF. Fungal Infections Potentiated by Biologics. Infect Dis Clin North Am 2020;34:389-411. [PMID: 32334987 DOI: 10.1016/j.idc.2020.02.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
372 Silva NOE, de Brito BB, da Silva FAF, Santos MLC, de Melo FF. Probiotics in inflammatory bowel disease: Does it work? World J Meta-Anal 2020; 8(2): 54-66 [DOI: 10.13105/wjma.v8.i2.54] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
373 Moon W, Pestana L, Becker B, Loftus EV, Hanson KA, Bruining DH, Tremaine WJ, Kane SV. Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice. Aliment Pharmacol Ther. 2015;42:428-440. [PMID: 26081839 DOI: 10.1111/apt.13288] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
374 Riis A, Martinsen TC, Waldum HL, Fossmark R. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. Scand J Gastroenterol. 2012;47:649-657. [PMID: 22472026 DOI: 10.3109/00365521.2012.672591] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
375 Kulkarni C, Murag S, Cholankeril G, Fardeen T, Mannalithara A, Lerrigo R, Kamal A, Ahmed A, Goel A, Sinha SR. Association of Anti-TNF Therapy With Increased Risk of Acute Cholangitis in Patients With Primary Sclerosing Cholangitis. Inflamm Bowel Dis 2021;27:1602-9. [PMID: 33300561 DOI: 10.1093/ibd/izaa317] [Reference Citation Analysis]
376 Larussa T, Basile A, Palleria C, Iannelli C, Vero A, Giubilei L, De Sarro C, Suraci E, Marasco R, Imeneo M, Russo E, Abenavoli L, De Sarro G, Luzza F. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. Med Pharm Rep 2021;94:289-97. [PMID: 34430850 DOI: 10.15386/mpr-1897] [Reference Citation Analysis]
377 Zois CD, Katsanos KH, Kosmidou M, Tsianos EV. Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights. J Crohns Colitis 2010;4:115-24. [PMID: 21122494 DOI: 10.1016/j.crohns.2009.10.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
378 Kim JM, Kim DH, Park HJ, Ma HW, Park IS, Son M, Ro SY, Hong S, Han HK, Lim SJ, Kim SW, Cheon JH. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model. J Nanobiotechnology 2020;18:133. [PMID: 32933548 DOI: 10.1186/s12951-020-00693-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
379 Sands BE. New therapies for the treatment of inflammatory bowel disease. Surg Clin North Am. 2006;86:1045-1064. [PMID: 16905423 DOI: 10.1016/j.suc.2006.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
380 Faubion WA, Bousvaros A. Medical Therapy for Refractory Pediatric Crohn’s Disease. Clinical Gastroenterology and Hepatology 2006;4:1199-213. [DOI: 10.1016/j.cgh.2006.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
381 Homan M, Baldassano RN, Mamula P. Managing complicated Crohn's disease in children and adolescents. Nat Rev Gastroenterol Hepatol 2005;2:572-9. [DOI: 10.1038/ncpgasthep0338] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
382 Lichtenstein GR. Incorrect cost of infliximab in Crohn’s disease. Gastroenterology 2004;127:691-2. [DOI: 10.1053/j.gastro.2004.06.043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
383 Kilian A, Chock YP, Huang IJ, Graef ER, Upton LA, Khilnani A, Krupnikova SDS, Almaghlouth I, Cappelli LC, Fernandez-Ruiz R, Frankel BA, Frankovich J, Harrison C, Kumar B, Monga K, Vega JAR, Singh N, Sparks JA, Sullo E, Young KJ, Duarte-Garcia A, Putman M, Johnson S, Grainger R, Wallace ZS, Liew JW, Jayatilleke A. Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Semin Arthritis Rheum 2020;50:1191-201. [PMID: 32931985 DOI: 10.1016/j.semarthrit.2020.07.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
384 Allez M. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases]. Gastroenterol Clin Biol 2008;32:467-77. [PMID: 18448294 DOI: 10.1016/j.gcb.2008.03.002] [Reference Citation Analysis]
385 Feldman PA, Wolfson D, Barkin JS. Medical management of Crohn's disease. Clin Colon Rectal Surg 2007;20:269-81. [PMID: 20011423 DOI: 10.1055/s-2007-991026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
386 Pereira R, Lago P, Faria R, Torres T. Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy: SAFETY OF ANTI-TNF THERAPIES IN IMMUNE-MEDIATED INFLAMMATORY DISEASES. Drug Dev Res 2015;76:419-27. [DOI: 10.1002/ddr.21285] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
387 Schmidt KJ, Fellermann K, Wellhöner P, Weitz G, Homann N, Herrlinger K, Lehnert H, Ludwig D, Büning J. Clinical trial: cyclophosphamide pulse therapy - a promising therapeutic alternative in refractory Crohn’s disease. Alimentary Pharmacology & Therapeutics 2009;29:1230-9. [DOI: 10.1111/j.1365-2036.2009.03999.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
388 Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Current Opinion in Allergy & Clinical Immunology 2011;11:262-8. [DOI: 10.1097/aci.0b013e3283464bcd] [Cited by in Crossref: 52] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
389 Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T. Adalimumab in patients with Crohn’s disease--safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther. 2007;25:787-796. [PMID: 17373917 DOI: 10.1111/j.1365-2036.2007.03253.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
390 Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486-504. [PMID: 19628303 DOI: 10.1016/j.jaad.2008.10.060] [Cited by in Crossref: 124] [Cited by in F6Publishing: 92] [Article Influence: 9.5] [Reference Citation Analysis]
391 Chow DK, Sung JJ, Tsoi KK, Wong VW, Wu JC, Leong RW, Chan FK. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study. Aliment Pharmacol Ther. 2009;29:843-854. [PMID: 19154567 DOI: 10.1111/j.1365-2036.2009.03944.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
392 de Ridder L, Benninga MA, Taminiau JA, Hommes DW, van Deventer SJ. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:3-14. [PMID: 17592358 DOI: 10.1097/MPG.0b013e31803e171c] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 1.9] [Reference Citation Analysis]
393 Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013;228:18-28. [PMID: 23466067 DOI: 10.1016/j.atherosclerosis.2013.01.044] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 10.3] [Reference Citation Analysis]
394 Lima XT, Seidler EM, Lima HC, Kimball AB. Long-term safety of biologics in dermatology. Dermatologic Therapy 2009;22:2-21. [DOI: 10.1111/j.1529-8019.2008.01212.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
395 Larsen L, Drewes AM, Broberg MCH, Fallingborg J, Jacobsen BA, Jensen TB, Jess T. Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014. Inflamm Bowel Dis 2018;24:433-9. [PMID: 29361095 DOI: 10.1093/ibd/izx038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
396 Cucchiara S, Escher JC, Hildebrand H, Amil-dias J, Stronati L, Ruemmele FM. Pediatric Inflammatory Bowel Diseases and the Risk of Lymphoma: Should We Revise Our Treatment Strategies? Journal of Pediatric Gastroenterology & Nutrition 2009;48:257-67. [DOI: 10.1097/mpg.0b013e31818cf555] [Cited by in Crossref: 33] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
397 Lightner AL. Surgery for Inflammatory Bowel Disease in the Era of Biologics. J Gastrointest Surg 2020;24:1430-5. [PMID: 32253646 DOI: 10.1007/s11605-020-04563-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
398 Strauch U, Schölmerich J. Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs 2010;15:309-22. [PMID: 20402560 DOI: 10.1517/14728214.2010.480972] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
399 Thong BY, Vultaggio A, Rerkpattanapipat T, Schrijvers R. Prevention of Drug Hypersensitivity Reactions: Prescreening and Premedication. J Allergy Clin Immunol Pract 2021;9:2958-66. [PMID: 34366094 DOI: 10.1016/j.jaip.2021.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
400 Burke JP, Kelleher B, Ramadan S, Quinlan M, Sugrue D, O'Donovan MA. Pericarditis as a complication of infliximab therapy in Crohn's disease.Inflamm Bowel Dis. 2008;14:428-429. [PMID: 17924565 DOI: 10.1002/ibd.20270] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
401 Herfarth H. Infliximab in Crohnʼs disease: TREAT your friend as if he might become an enemy?: . Inflammatory Bowel Diseases 2007;13:933-4. [DOI: 10.1002/ibd.20120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
402 Srivastava MD, Alexander F, Tuthill RJ. Immunology of Cutaneous Vasculitis Associated with both Etanercept and Infliximab. Scand J Immunol 2005;61:329-36. [DOI: 10.1111/j.1365-3083.2005.01570.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
403 Namey M, Halper J, O'leary S, Beavin J, Bishop C. Best practices in multiple sclerosis: infusion reactions versus hypersensitivity associated with biologic therapies. J Infus Nurs 2010;33:98-111. [PMID: 20228647 DOI: 10.1097/NAN.0b013e3181cfd36d] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
404 Lu Y, Bousvaros A. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr. 2010;50:562-565. [PMID: 20639716 DOI: 10.1097/mpg.0b013e3181bab351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
405 Ramadan SM, Fouad TM, Summa V, Hasan SKh, Lo-Coco F. Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica 2012;97:805-17. [PMID: 22180424 DOI: 10.3324/haematol.2011.056283] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
406 Fiasse R, Dewit O. Novel therapies based on enhancement of gut innate immunity in inflammatory bowel disease. Expert Opinion on Therapeutic Patents 2007;17:1423-41. [DOI: 10.1517/13543776.17.12.1423] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
407 Cieplik N, Stangel M, Bachmann O. [Neurological complications of inflammatory bowel diseases]. Nervenarzt 2013;84:190-6. [PMID: 23392266 DOI: 10.1007/s00115-012-3682-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
408 de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:93-101. [PMID: 20134491 DOI: 10.1038/nrgastro.2009.221] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
409 Stein DJ, Ananthakrishnan AN, Issa M, Williams JB, Beaulieu DB, Zadvornova Y, Ward A, Johnson K, Knox JF, Skaros S, Binion DG. Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease. Inflamm Bowel Dis 2010;16:1173-9. [PMID: 19924800 DOI: 10.1002/ibd.21164] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
410 Nencini F, Vultaggio A, Pratesi S, Cammelli D, Milla M, Fiori G, Bagnoli S, Prignano F, Romagnani S, Maggi E, Matucci A. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. The Journal of Allergy and Clinical Immunology: In Practice 2018;6:2065-2072.e2. [DOI: 10.1016/j.jaip.2018.04.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
411 Carter MJ, Lobo AJ, Travis SP; IBD Section; British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1-16. [PMID: 15306569 DOI: 10.1136/gut.2004.043372] [Cited by in Crossref: 700] [Cited by in F6Publishing: 644] [Article Influence: 38.9] [Reference Citation Analysis]
412 Kong JS, Teuber SS, Gershwin ME. Potential adverse events with biologic response modifiers. Autoimmun Rev 2006;5:471-85. [PMID: 16920574 DOI: 10.1016/j.autrev.2006.02.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
413 Mascheretti S, Schreiber S. The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease. Pharmacogenomics 2004;5:479-86. [PMID: 15212584 DOI: 10.1517/14622416.5.5.479] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
414 Sattler L, Hanauer SB, Malter L. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep 2021;23:30. [PMID: 34913108 DOI: 10.1007/s11894-021-00829-y] [Reference Citation Analysis]
415 Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51:1202-1207; discussion 1202-1210. [PMID: 18536964 DOI: 10.1007/s10350-008-9364-7] [Cited by in Crossref: 204] [Cited by in F6Publishing: 160] [Article Influence: 14.6] [Reference Citation Analysis]
416 Rosenberg LN, Peppercorn MA. Efficacy and safety of drugs for ulcerative colitis. Expert Opinion on Drug Safety 2010;9:573-92. [DOI: 10.1517/14740331003639412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
417 Siegel CA. Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis 2010;16:2168-72. [PMID: 20848508 DOI: 10.1002/ibd.21305] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
418 Otley A, Critch J, Butzner JD. Infliximab for the treatment of paediatric Crohn's disease: Obstacles to accessing a necessary therapy. Paediatr Child Health 2004;9:87-9. [PMID: 19654986 DOI: 10.1093/pch/9.2.87] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
419 Donovan M, Lunney K, Carter-Pokras O, Cross RK. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci 2007;52:1798-805. [PMID: 17417731 DOI: 10.1007/s10620-006-9269-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
420 Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52:1481-1484. [PMID: 17429728 DOI: 10.1007/s10620-006-9250-x] [Cited by in Crossref: 153] [Cited by in F6Publishing: 125] [Article Influence: 10.2] [Reference Citation Analysis]
421 Swoger JM, Regueiro M. Stopping, Continuing, or Restarting Immunomodulators and Biologics When an Infection or Malignancy Develops: . Inflammatory Bowel Diseases 2014;20:926-35. [DOI: 10.1097/mib.0000000000000002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
422 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
423 Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130:1054-1061. [PMID: 16618399 DOI: 10.1053/j.gastro.2006.02.014] [Cited by in Crossref: 271] [Cited by in F6Publishing: 239] [Article Influence: 16.9] [Reference Citation Analysis]
424 Zullow S, Farraye FA. Updates on vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol 2019;13:229-39. [PMID: 30791761 DOI: 10.1080/17474124.2019.1565993] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
425 Kamel AY, Concepcion O, Schlachterman A, Glover S, Forsmark CY. Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease. ACG Case Rep J 2016;3:187-9. [PMID: 27144200 DOI: 10.14309/crj.2016.45] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
426 Laharie D, Salzmann M, Boubekeur H, Richy F, Amouretti M, Quinton A, Couzigou P, Lamouliatte H, Zerbib F. Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol Clin Biol 2005;29:145-9. [PMID: 15795662 DOI: 10.1016/s0399-8320(05)80718-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
427 Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol. 2007;47:930-941. [PMID: 17567930 DOI: 10.1177/0091270007301623] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 5.6] [Reference Citation Analysis]
428 Coutzac C, Chapuis J, Poullenot F, Chabrun E, Capdepont M, Blanco P, Laharie D. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study. J Crohns Colitis 2015;9:982-7. [PMID: 26351388 DOI: 10.1093/ecco-jcc/jjv159] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
429 Stübgen JP. Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies. J Neurol 2011;258:961-70. [PMID: 21253756 DOI: 10.1007/s00415-011-5907-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
430 Matsuda J, Kaburaki T, Kobayashi S, Numaga J. Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis. Jpn J Ophthalmol 2013;57:104-7. [DOI: 10.1007/s10384-012-0202-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
431 Atienza P. Fistules ano-périnéales réfractaires de la maladie de Crohn. Gastroentérologie Clinique et Biologique 2007;31:404-11. [DOI: 10.1016/s0399-8320(07)89400-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
432 Ducharme J, Pelletier C, Zacharias R. Premedications for infliximab infusions do not impact the risk of acute adverse drug reactions. Frontline Gastroenterol 2011;2:249-54. [PMID: 28839619 DOI: 10.1136/flgastro-2011-100030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
433 Wetter DA, Davis MD. Lupus-Like Syndrome Attributable to Anti—Tumor Necrosis Factor α Therapy in 14 Patients During an 8-Year Period at Mayo Clinic. Mayo Clinic Proceedings 2009;84:979-84. [DOI: 10.1016/s0025-6196(11)60668-x] [Cited by in Crossref: 83] [Article Influence: 6.4] [Reference Citation Analysis]
434 Ismail WA, Al-enzy SA, Alsurayei SA, Ismail AE. Vitiligo in a patient receiving infliximab for refractory ulcerative colitis. Arab Journal of Gastroenterology 2011;12:109-11. [DOI: 10.1016/j.ajg.2011.03.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
435 Zabana Y, Garcia-planella E, van Domselaar M, Mañosa M, Gordillo J, López-sanromán A, Cabré E, Domènech E. Predictors of favourable outcome in inflammatory Crohn's disease. A retrospective observational study. Gastroenterología y Hepatología 2013;36:616-23. [DOI: 10.1016/j.gastrohep.2013.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
436 Manitrala Ramanampamonjy R, Laharie D, Bonnefoy B, Vergniol J, Amouretti M. Méningoencéphalite à Listeria monocytogenes au cours d’un traitement par infliximab d’une maladie de Crohn. Gastroentérologie Clinique et Biologique 2006;30:157-8. [DOI: 10.1016/s0399-8320(06)73138-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
437 Siddiki HA, Fidler JL, Fletcher JG, Burton SS, Huprich JE, Hough DM, Johnson CD, Bruining DH, Loftus EV, Sandborn WJ. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn’s disease. AJR Am J Roentgenol. 2009;193:113-121. [PMID: 19542402 DOI: 10.2214/ajr.08.2027] [Cited by in Crossref: 281] [Cited by in F6Publishing: 70] [Article Influence: 21.6] [Reference Citation Analysis]
438 Braun J, Baraliakos X, Brandt J, Sieper J. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 2005;34:178-90. [PMID: 16134723 DOI: 10.1080/03009740510026599] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
439 Lorenzo-Vizcaya A, Isenberg DA. The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now? Expert Opin Biol Ther 2021;21:639-47. [PMID: 33216641 DOI: 10.1080/14712598.2021.1853096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
440 Wagner CA, Roqué PJ, Goverman JM. Pathogenic T cell cytokines in multiple sclerosis. J Exp Med 2020;217:e20190460. [PMID: 31611252 DOI: 10.1084/jem.20190460] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
441 Bye WA, Sparrow MP, Connor SJ, Andrews JM, Ellard K, Ng W, Hume G, Antoniades S, Walsh AJ. The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus: Herpes zoster vaccine in IBD patients. Intern Med J 2017;47:1263-9. [DOI: 10.1111/imj.13488] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
442 Myśliwiec M, Balcerska A, Zorena K, Myśliwska J, Lipowski P, Raczyńska K. The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy. Diabetes Res Clin Pract 2008;79:141-6. [PMID: 17716775 DOI: 10.1016/j.diabres.2007.07.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
443 Johnson FR, Ozdemir S, Mansfield C, Hass S, Siegel CA, Sands BE. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal 2009;29:121-36. [PMID: 18826414 DOI: 10.1111/j.1539-6924.2008.01135.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
444 Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr. 2005;40:220-222. [PMID: 15699701 DOI: 10.1097/00005176-200502000-00026] [Cited by in Crossref: 111] [Cited by in F6Publishing: 89] [Article Influence: 6.5] [Reference Citation Analysis]
445 Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048] [Cited by in Crossref: 328] [Cited by in F6Publishing: 303] [Article Influence: 20.5] [Reference Citation Analysis]
446 Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D; Foie-Alcool group of the Association Française pour l'Etude du Foie. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;39:1390-7. [PMID: 15122768 DOI: 10.1002/hep.20206] [Cited by in Crossref: 280] [Cited by in F6Publishing: 253] [Article Influence: 15.6] [Reference Citation Analysis]
447 Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366-73. [PMID: 15306602 DOI: 10.1136/gut.2003.025452] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
448 Panés J, Gomollón F, Taxonera C, Hinojosa J, Clofent J, Nos P. Crohn's disease: a review of current treatment with a focus on biologics. Drugs 2007;67:2511-37. [PMID: 18034589 DOI: 10.2165/00003495-200767170-00005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
449 Lightner AL, Grass F, Alsughayer AM, Harmsen WS, Petersen M, Loftus EV Jr. Are Biologics Safe in the Immediate Postoperative Period? A Single-Center Evaluation of Consecutive Crohn's Surgical Patients. Dis Colon Rectum 2020;63:934-43. [PMID: 32149787 DOI: 10.1097/DCR.0000000000001649] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
450 El-hussuna A, Andersen J, Bisgaard T, Jess P, Henriksen M, Oehlenschlager J, Thorlacius-ussing O, Olaison G. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease. Scandinavian Journal of Gastroenterology 2012;47:662-8. [DOI: 10.3109/00365521.2012.660540] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
451 Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004;64:1767-1777. [PMID: 15301561 DOI: 10.2165/00003495-200464160-00004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
452 de Vries HS, van Oijen MG, de Jong DJ. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf 2008;31:1135-44. [PMID: 19026030 DOI: 10.2165/0002018-200831120-00009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
453 James DG, Stone CD, Wang HL, Stenson WF. Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006;12:573-80. [PMID: 16804394 DOI: 10.1097/01.MIB.0000225333.83861.16] [Cited by in Crossref: 37] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
454 Nuij VJAA, Peppelenbosch MP, van der Woude CJ, Fuhler GM. Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease. J Transl Med 2017;15:248. [PMID: 29228965 DOI: 10.1186/s12967-017-1355-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
455 Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006;23:451-463. [PMID: 16441465 DOI: 10.1111/j.1365-2036.2006.02786.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 162] [Article Influence: 10.5] [Reference Citation Analysis]
456 Bodily KD, Fletcher JG, Solem CA, Johnson CD, Fidler JL, Barlow JM, Bruesewitz MR, McCollough CH, Sandborn WJ, Loftus EV. Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology. 2006;238:505-516. [PMID: 16436815 DOI: 10.1148/radiol.2382041159] [Cited by in Crossref: 271] [Cited by in F6Publishing: 216] [Article Influence: 16.9] [Reference Citation Analysis]
457 Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 2013;57:1318-30. [PMID: 23899685 DOI: 10.1093/cid/cit489] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
458 Hayee B, Rahman FZ, Sewell G, Smith AM, Segal AW. Crohn's disease as an immunodeficiency. Expert Rev Clin Immunol 2010;6:585-96. [PMID: 20594132 DOI: 10.1586/eci.10.32] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
459 Dignass A, Van Assche G, Lindsay J, Lémann M, Söderholm J, Colombel J, Danese S, D'hoore A, Gassull M, Gomollón F, Hommes D, Michetti P, O'morain C, Öresland T, Windsor A, Stange E, Travis S. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's and Colitis 2010;4:28-62. [DOI: 10.1016/j.crohns.2009.12.002] [Cited by in Crossref: 981] [Cited by in F6Publishing: 886] [Article Influence: 81.8] [Reference Citation Analysis]
460 Jacobstein DA, Markowitz JE, Kirschner BS, Ferry G, Cohen SA, Gold BD, Winter HS, Heyman MB, Baldassano RN. Premedication and Infusion Reactions With Infliximab: Results From a Pediatric Inflammatory Bowel Disease Consortium: . Inflammatory Bowel Diseases 2005;11:442-6. [DOI: 10.1097/01.mib.0000158166.88238.ea] [Cited by in Crossref: 65] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
461 Ross H, Steele SR, Varma M, Dykes S, Cima R, Buie WD, Rafferty J. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2014;57:5-22. [PMID: 24316941 DOI: 10.1097/dcr.0000000000000030] [Cited by in Crossref: 107] [Cited by in F6Publishing: 27] [Article Influence: 13.4] [Reference Citation Analysis]
462 Falconer H, Mwenda JM, Chai DC, Song XR, Cornillie FJ, Bergqvist A, Fried G, D'hooghe TM. Effects of anti-TNF-mAb treatment on pregnancy in baboons with induced endometriosis. Fertility and Sterility 2008;89:1537-45. [DOI: 10.1016/j.fertnstert.2007.05.062] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
463 O'Donnell S, Murphy S, Anwar MM, O'Sullivan M, Breslin N, O'Connor HJ, Ryan BM, O'Morain CA. Safety of infliximab in 10 years of clinical practice. Eur J Gastroenterol Hepatol 2011;23:603-6. [PMID: 21602689 DOI: 10.1097/MEG.0b013e3283479125] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
464 Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
465 Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 51-65 [PMID: 26855812 DOI: 10.4292/wjgpt.v7.i1.51] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
466 Devaraj B, Kaiser AM. Surgical management of ulcerative colitis in the era of biologicals. Inflamm Bowel Dis 2015;21:208-20. [PMID: 25222665 DOI: 10.1097/MIB.0000000000000178] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
467 Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc. 2011;86:748-757. [PMID: 21803957 DOI: 10.4065/mcp.2011.0074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
468 Melek J, Štanclová M, Dědek P, Malý J, Bayer M, Pozler O, Bureš J. Infliximab plus azathioprine is more effective than azathioprine alone in achieving mucosal healing in pediatric patients with Crohn's disease. J Dig Dis 2020;21:705-10. [PMID: 32755026 DOI: 10.1111/1751-2980.12927] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
469 Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study. Inflamm Bowel Dis 2015;21:1847-53. [PMID: 25993693 DOI: 10.1097/MIB.0000000000000457] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
470 Bourré-Tessier J, Fortin C, Belisle A, Desmarais E, Choquette D, Senécal JL. Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept. Scand J Rheumatol 2009;38:311-6. [PMID: 19444717 DOI: 10.1080/03009740902776935] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
471 Pagnini C, Arseneau KO, Cominelli F. Safety considerations when using anti-TNFα therapy to treat Crohn's disease. Expert Opin Drug Saf 2015;14:31-44. [PMID: 25400161 DOI: 10.1517/14740338.2015.976610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
472 Szymanska E, Dadalski M, Oracz G, Kierkus J. Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease. Prz Gastroenterol 2015;10:164-8. [PMID: 26516383 DOI: 10.5114/pg.2015.52298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
473 Bermejo PE, Burgos A. [Neurological complications of inflammatory bowel disease]. Med Clin (Barc) 2008;130:666-75. [PMID: 18501131 DOI: 10.1157/13120693] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
474 Khanna R, Feagan BG. Ustekinumab for the treatment of Crohn’s disease. Immunotherapy. 2013;5:803-815. [PMID: 23902548 DOI: 10.2217/imt.13.81] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
475 Seminerio JL, Loftus EV, Colombel JF, Thapa P, Sandborn WJ. Infliximab for Crohn’s disease: the first 500 patients followed up through 2009. Dig Dis Sci. 2013;58:797-806. [PMID: 23053885 DOI: 10.1007/s10620-012-2405-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
476 Shen EH, Das KM. Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 2004;38:741-5. [PMID: 15365397 DOI: 10.1097/01.mcg.0000140188.88275.65] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
477 Aberra FN, Lichtenstein GR. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:685-695. [PMID: 15973124 DOI: 10.1097/01.mib.0000160742.91602.b7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
478 Barbato M, Curione M, Viola F, Versacci P, Parisi F, Amato S, Cucchiara S. Cardiac involvement in children with IBD during infliximab therapy: . Inflammatory Bowel Diseases 2006;12:828-9. [DOI: 10.1097/00054725-200608000-00021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
479 Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L, Cochrane CJ, Aitken S, Fennell J, Rogers P. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009;29:286-297. [PMID: 19132970 DOI: 10.1111/j.1365-2036.2008.03882.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 6.9] [Reference Citation Analysis]
480 Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46:645-60. [PMID: 17655372 DOI: 10.2165/00003088-200746080-00002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 144] [Article Influence: 11.1] [Reference Citation Analysis]
481 Eder P, Niezgódka A, Krela-Kaźmierczak I, Stawczyk-Eder K, Banasik E, Dobrowolska A. Dietary Support in Elderly Patients with Inflammatory Bowel Disease. Nutrients 2019;11:E1421. [PMID: 31238597 DOI: 10.3390/nu11061421] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
482 Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656. [PMID: 16530505 DOI: 10.1053/j.gastro.2005.12.019] [Cited by in Crossref: 580] [Cited by in F6Publishing: 527] [Article Influence: 36.3] [Reference Citation Analysis]
483 Hudesman D, Lichtiger S, Sands B. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature. Inflamm Bowel Dis 2013;19:644-9. [PMID: 23314243 DOI: 10.1097/MIB.0b013e318280ebbd] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
484 Kevans D, Keegan D, Mulcahy HE, O'donoghue DP. Infliximab therapy in Crohn's disease: a pragmatic approach? Aliment Pharmacol Ther 2006;24:351-9. [DOI: 10.1111/j.1365-2036.2006.02979.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
485 Kim JH, Kim JW. Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease. Korean J Gastroenterol 2017;70:162. [DOI: 10.4166/kjg.2017.70.4.162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
486 Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE—Promising or crazy? Autoimmunity Reviews 2012;11:321-5. [DOI: 10.1016/j.autrev.2011.05.001] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
487 Higashiyama M, Sugita A, Koganei K, Wanatabe K, Yokoyama Y, Uchino M, Nagahori M, Naganuma M, Bamba S, Kato S, Takeuchi K, Omori T, Takagi T, Matsumoto S, Nagasaka M, Sagami S, Kitamura K, Katsurada T, Sugimoto K, Takatsu N, Saruta M, Sakurai T, Watanabe K, Nakamura S, Suzuki Y, Hokari R. Management of elderly ulcerative colitis in Japan. J Gastroenterol 2019;54:571-86. [PMID: 31025187 DOI: 10.1007/s00535-019-01580-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
488 Blonski W, Lichtenstein GR. Safety of biologic therapy: . Inflammatory Bowel Diseases 2007;13:769-96. [DOI: 10.1002/ibd.20027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
489 Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, Ananthakrishnan AN. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:309-15. [PMID: 22605668 DOI: 10.1002/ibd.23026] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 9.8] [Reference Citation Analysis]
490 Feuerstein JD, Cheifetz AS. Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy). Gastroenterology Clinics of North America 2014;43:543-63. [DOI: 10.1016/j.gtc.2014.05.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
491 Byrne CM, Solomon MJ, Young JM, Selby W, Harrison JD. Patient Preferences Between Surgical and Medical Treatment in Crohn's Disease. Diseases of the Colon & Rectum 2007;50:586-97. [DOI: 10.1007/s10350-006-0847-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
492 Betteridge JD, Veerappan GR. Pulmonary carcinoid tumor in a patient on adalimumab for Crohn's disease. Inflamm Bowel Dis 2013;19:E29-30. [PMID: 22447376 DOI: 10.1002/ibd.22913] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
493 Coe CL, Horst SN, Izzy MJ. Neurologic Toxicities Associated with Tumor Necrosis Factor Inhibitors and Calcineurin Inhibitors. Neurol Clin 2020;38:937-51. [PMID: 33040870 DOI: 10.1016/j.ncl.2020.07.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
494 Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7:55-63. [PMID: 21162650 DOI: 10.1586/eci.10.90] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 6.9] [Reference Citation Analysis]
495 Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936. [PMID: 18294633 DOI: 10.1053/j.gastro.2008.01.012] [Cited by in Crossref: 647] [Cited by in F6Publishing: 589] [Article Influence: 46.2] [Reference Citation Analysis]
496 Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630. [PMID: 16678077 DOI: 10.1016/j.cgh.2006.03.002] [Cited by in Crossref: 633] [Cited by in F6Publishing: 547] [Article Influence: 39.6] [Reference Citation Analysis]
497 Coffin CS, Fraser HF, Panaccione R, Ghosh S. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:479-484. [PMID: 20848520 DOI: 10.1002/ibd.21336] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
498 Kuehn F, Mullins CS, Krohn M, Harnack C, Ramer R, Krämer OH, Klar E, Huehns M, Linnebacher M. Establishment and characterization of HROC69 - a Crohn´s related colonic carcinoma cell line and its matched patient-derived xenograft. Sci Rep 2016;6:24671. [PMID: 27087592 DOI: 10.1038/srep24671] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
499 de Ridder L, Benninga MA, Taminiau JAJM, Hommes DW. Infliximab as First-Line Therapy in Severe Pediatric Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2006;43:388-90. [DOI: 10.1097/01.mpg.0000226369.31956.bf] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
500 Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, De Vitis I, Guidi L, Gasbarrini A. Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol. 2009;104:1575-1586. [PMID: 19491875 DOI: 10.1038/ajg.2009.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
501 Fukuda Y, Takazoe M, Sugita A, Kosaka T, Kinjo F, Otani Y, Fujii H, Koganei K, Makiyama K, Nakamura T, Suda T, Yamamoto S, Ashida T, Majima A, Morita N, Murakami K, Oshitani N, Takahama K, Tochihara M, Tsujikawa T, Watanabe M. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2008;103:1721-9. [PMID: 18616656 DOI: 10.1111/j.1572-0241.2008.01860.x] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
502 Loftus EV. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time. Am J Gastroenterol 2005;100:1435-8. [PMID: 15984960 DOI: 10.1111/j.1572-0241.2005.50622_2.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
503 Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol. 2011;106:1889-1897. [PMID: 21862997 DOI: 10.1038/ajg.2011.271] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
504 Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol. 2008;43:948-954. [PMID: 19086165 DOI: 10.1080/00365520801957149] [Cited by in Crossref: 194] [Cited by in F6Publishing: 178] [Article Influence: 14.9] [Reference Citation Analysis]
505 Panteris V, Perdiou A, Tsirimpis V, Karamanolis DG. Acute coronary syndrome after infliximab therapy in a patient with Crohn’s disease. World J Gastroenterol 2006; 12(38): 6235-6238 [PMID: 17036404 DOI: 10.3748/wjg.v12.i38.6235] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
506 Atienza P, Ksiaa M. Particular aspects of proctology for anoperineal lesions in Crohn's disease. J Visc Surg 2015;152:S45-53. [PMID: 25687623 DOI: 10.1016/j.jviscsurg.2015.01.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
507 Billioud V, Peyrin-biroulet L. Can elderly people be treated safely with anti-TNF agents?: . Inflammatory Bowel Diseases 2012;18:594-5. [DOI: 10.1002/ibd.21771] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
508 Lu DG, Ji XQ, Liu X, Li HJ, Zhang CQ. Pulmonary manifestations of Crohn’s disease. World J Gastroenterol 2014; 20(1): 133-141 [PMID: 24415866 DOI: 10.3748/wjg.v20.i1.133] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
509 Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol 2008;22:261-72. [PMID: 18354755 DOI: 10.1155/2008/493405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
510 Cullen G, Vaughn B, Ahmed A, Peppercorn MA, Smith MP, Moss AC, Cheifetz AS. Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy. Inflamm Bowel Dis 2012;18:691-6. [PMID: 21648022 DOI: 10.1002/ibd.21783] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
511 Thaler K, Chandiramani DV, Hansen RA, Gartlehner G. Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics 2009;3:485-98. [PMID: 20054439 DOI: 10.2147/btt.2009.3755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
512 Crum NF, Lederman ER, Wallace MR. Infections Associated With Tumor Necrosis Factor-α Antagonists. Medicine 2005;84:291-302. [DOI: 10.1097/01.md.0000180044.19285.9a] [Cited by in Crossref: 141] [Cited by in F6Publishing: 95] [Article Influence: 8.3] [Reference Citation Analysis]
513 Kochhar R, Gupta V, Dutta U, Singh K, Kochhar R. Infliximab induced endophthalmitis in a patient of fistulizing Crohn's disease. Indian J Gastroenterol. 2011;30:241-242. [PMID: 21932073 DOI: 10.1007/s12664-011-0130-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
514 Wiese DM, Rivera R, Seidner DL. Is There a Role for Bowel Rest in Nutrition Management of Crohn's Disease? Nutr Clin Pract 2008;23:309-17. [DOI: 10.1177/0884533608318674] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
515 Kornbluth A, Sachar DB;  Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23; quiz 524. [PMID: 20068560 DOI: 10.1038/ajg.2009.727] [Cited by in Crossref: 826] [Cited by in F6Publishing: 730] [Article Influence: 68.8] [Reference Citation Analysis]
516 Théophile H, Schaeverbeke T, Miremont-Salamé G, Abouelfath A, Kahn V, Haramburu F, Bégaud B. Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system. Drug Saf 2011;34:577-85. [PMID: 21663333 DOI: 10.2165/11590200-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
517 Subramaniam K, D'Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol. 2013;28:24-30. [PMID: 23094824 DOI: 10.1111/jgh.12015] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
518 Lebas D, Staumont-sallé D, Solau-gervais E, Flipo R, Delaporte E. Manifestations cutanées observées au cours d’un traitement par anti-TNF alpha : 11 observations. Annales de Dermatologie et de Vénéréologie 2007;134:337-42. [DOI: 10.1016/s0151-9638(07)89187-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 3] [Article Influence: 2.2] [Reference Citation Analysis]
519 Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83:181-194. [PMID: 18241628 DOI: 10.1016/s0025-6196(11)60839-2] [Cited by in Crossref: 196] [Cited by in F6Publishing: 2] [Article Influence: 14.0] [Reference Citation Analysis]
520 Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, Gjertson D, Braun J, Reed E, Singh RR. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126:121-136. [PMID: 17916444 DOI: 10.1016/j.clim.2007.08.013] [Cited by in Crossref: 182] [Cited by in F6Publishing: 182] [Article Influence: 12.1] [Reference Citation Analysis]
521 Löwenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Drugs. 2006;66:1431-1439. [PMID: 16906776 DOI: 10.2165/00003495-200666110-00002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
522 Balmus IM, Ciobica A, Trifan A, Stanciu C. The implications of oxidative stress and antioxidant therapies in Inflammatory Bowel Disease: Clinical aspects and animal models. Saudi J Gastroenterol. 2016;22:3-17. [PMID: 26831601 DOI: 10.4103/1319-3767.173753] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 20.8] [Reference Citation Analysis]
523 Devlin SM, Panaccione R. Adalimumab for the treatment of Crohn's disease. Expert Opin Biol Ther 2008;8:1011-9. [PMID: 18549330 DOI: 10.1517/14712598.8.7.1011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
524 Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, Bigard MA, Hébuterne X, Treton X, Kohn A. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92-101. [PMID: 19709098 DOI: 10.1111/j.1365-2036.2009.04130.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 6.7] [Reference Citation Analysis]
525 Puertas-Abreu E, Polanco ER, Azocar M, Mundarain LA, Nuñez-Sotelo CM, Montaño R, Vivas FH, Noguera ZT, Marín F, Bellorin O, Rivas JG, Toro E, Benzaquen E, Rauseo M, Gutiérrez González LA; GRUPO GRUVES: grupo Venezolano para el Estudio de las Espondiloartritis. Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α. Int Arch Med 2012;5:7. [PMID: 22336076 DOI: 10.1186/1755-7682-5-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
526 Banerji A, Brennan P, Hesterberg P, Oren E, Hsu FI. Drug Desensitizations in the Management of Allergy and Anaphylaxis to Chemotherapeutic Agents and Monoclonal Antibodies. In: Castells MC, editor. Anaphylaxis and Hypersensitivity Reactions. Totowa: Humana Press; 2011. pp. 297-311. [DOI: 10.1007/978-1-60327-951-2_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
527 Calbo E, Garau J. Of mice and men: innate immunity in pneumococcal pneumonia. Int J Antimicrob Agents 2010;35:107-13. [PMID: 20005681 DOI: 10.1016/j.ijantimicag.2009.10.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
528 Lashner BA, Brzezinski A. Crohn's Disease. GI/Liver Secrets. Elsevier; 2010. pp. 297-303. [DOI: 10.1016/b978-0-323-06397-5.00042-3] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
529 Setoyama H, Ido A, Numata M, Moriuchi A, Yamaji N, Tamai T, Funakawa K, Fujita H, Sakiyama T, Uto H, Oketani M, Tsubouchi H. Repeated enemas with hepatocyte growth factor selectively stimulate epithelial cell proliferation of injured mucosa in rats with experimental colitis. Life Sci 2011;89:269-75. [PMID: 21763320 DOI: 10.1016/j.lfs.2011.06.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
530 Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, Lechago J, Paavola J, Loane J, Lee SK. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004;10:333-338. [PMID: 15475739 DOI: 10.1097/00054725-200407000-00002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 69] [Article Influence: 4.6] [Reference Citation Analysis]
531 Schmidt LA, Lim MS. T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary. J Hematop. 2009;2:121-126. [PMID: 19669196 DOI: 10.1007/s12308-009-0029-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
532 D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007;56:725-32. [PMID: 17440187 DOI: 10.1136/gut.2006.103564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
533 Gleeson F, Clarke E, Kelly S, Hargadan G, Kenny E, Macmathuna P, Lennon J. Diagnosis by EUS trucut biopsy of extrapulmonary tuberculosis in a patient with Crohn's disease treated with infliximab. Gastrointestinal Endoscopy 2005;61:489-92. [DOI: 10.1016/s0016-5107(04)02641-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
534 Jones-Hall YL, Kozik A, Nakatsu C. Ablation of tumor necrosis factor is associated with decreased inflammation and alterations of the microbiota in a mouse model of inflammatory bowel disease. PLoS One 2015;10:e0119441. [PMID: 25775453 DOI: 10.1371/journal.pone.0119441] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
535 Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:607-20. [PMID: 20594134 DOI: 10.1586/eci.10.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
536 Duricova D, Pedersen N, Elkjaer M, Jensen JKS, Munkholm P. 5-Aminosalicylic acid dependency in Crohn's disease: A Danish Crohn Colitis Database study. Journal of Crohn's and Colitis 2010;4:575-81. [DOI: 10.1016/j.crohns.2010.06.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
537 Desalermos AP, Farraye FA, Wasan SK. Vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol 2015;9:91-102. [PMID: 25160668 DOI: 10.1586/17474124.2014.934672] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
538 Zella GC, Weinblatt ME, Winter HS. Drug-induced Lupus Associated With Infliximab and Adalimumab in an Adolescent With Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2009;49:355-8. [DOI: 10.1097/mpg.0b013e3181837289] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
539 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
540 Subramanian V, Pollok RCG, Kang J, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. British Journal of Surgery 2006;93:793-9. [DOI: 10.1002/bjs.5375] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
541 Rufini S, Ciccacci C, Novelli G, Borgiani P. Pharmacogenetics of inflammatory bowel disease: a focus on Crohn's disease. Pharmacogenomics 2017;18:1095-114. [PMID: 28686143 DOI: 10.2217/pgs-2017-0068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
542 Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum. 2007;50:1754-1760. [PMID: 17899271 DOI: 10.1007/s10350-007-9077-3] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 5.3] [Reference Citation Analysis]
543 Tissot B, Visée S, Pilette C, Prophette B, Puechal X. Lymphocytic meningitis with infliximab for ulcerative colitis. Gastroentérologie Clinique et Biologique 2006;30:1420-2. [DOI: 10.1016/s0399-8320(06)73577-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
544 Hyman NH. Crohn's disease: drug therapy or surgery? Expert Rev Gastroenterol Hepatol. 2007;1:187-192. [PMID: 19072408 DOI: 10.1586/17474124.1.2.187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
545 Pozadzides JV, Pro B. Hepatosplenic T-cell lymphoma and TNF-α inhibitors. Expert Rev Hematol 2009;2:611-4. [PMID: 21082951 DOI: 10.1586/ehm.09.62] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
546 Uthman I, Touma Z, El-sayyad J, Zaitoun F. Successful retreatment with infliximab in patients with prior severe infusion reactions. Clin Rheumatol 2006;25:540-1. [DOI: 10.1007/s10067-005-0029-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
547 Xiao L, Sun L, Zhao K, Pan YS. Crohn’s disease with infliximab treatment complicated by rapidly progressing colorectal cancer: A case report. World J Gastrointest Oncol 2021; 13(4): 305-311 [PMID: 33889281 DOI: 10.4251/wjgo.v13.i4.305] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
548 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
549 Navaneethan U, Edminister T, Zhu X, Kommaraju K, Glover S. Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:E17. [PMID: 28296827 DOI: 10.1097/MIB.0000000000001071] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 5.8] [Reference Citation Analysis]
550 Bussel JB, Giulino L, Lee S, Patel VL, Sandborg C, Stiehm ER. Update on therapeutic monoclonal antibodies. Curr Probl Pediatr Adolesc Health Care 2007;37:118-35. [PMID: 17434008 DOI: 10.1016/j.cppeds.2007.02.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
551 Sorrentino D, Terrosu G, Avellini C. Infliximab in Crohn's disease: a look at the (not so distant) future. Dig Liver Dis 2008;40 Suppl 2:S229-35. [PMID: 18598994 DOI: 10.1016/S1590-8658(08)60531-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
552 Su KY, Tsai ST, Tsay SH, Lee HT, Chen WS, Huang DF. A patient with systemic lupus erythematosus and Crohn's disease complicated with massive lower gastrointestinal bleeding, mimicking intestinal vasculitis. Lupus 2008;17:1049-50. [PMID: 18852232 DOI: 10.1177/0961203308091966] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
553 Byun JM, Lee CK, Rhee SY, Kim H, Im JP, Park DI, Eun CS, Jung S, Shin JE, Lee K, Cheon JH. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor. Scandinavian Journal of Gastroenterology 2014;50:312-20. [DOI: 10.3109/00365521.2014.1000960] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
554 del Rio B, Redruello B, Fernandez M, Martin MC, Ladero V, Alvarez MA. Lactic Acid Bacteria as a Live Delivery System for the in situ Production of Nanobodies in the Human Gastrointestinal Tract. Front Microbiol 2019;9:3179. [DOI: 10.3389/fmicb.2018.03179] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
555 Chen Y, Wu H, Liau W, Tsai C, Tsai H, Chao K, Sung Y, Li H. A tumor necrosis factor-α inhibitor reduces the embryotoxic effects of endometriotic peritoneal fluid. Fertility and Sterility 2013;100:1476-1485.e5. [DOI: 10.1016/j.fertnstert.2013.07.1985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
556 Jauregui-Amezaga A, Turon F, Ordás I, Gallego M, Feu F, Ricart E, Panés J. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis. 2013;7:208-212. [PMID: 22677117 DOI: 10.1016/j.crohns.2012.05.012] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 6.4] [Reference Citation Analysis]
557 Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008;159:527-36. [PMID: 18627374 DOI: 10.1111/j.1365-2133.2008.08728.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 4.6] [Reference Citation Analysis]
558 Kohli R, Melin-Aldana H, Sentongo TA. Mesalamine-induced pneumonitis during therapy for chronic inflammatory bowel disease: a pediatric case report. J Pediatr Gastroenterol Nutr. 2005;41:479-482. [PMID: 16205520 DOI: 10.1097/01.mpg.0000173601.31647.84] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
559 Chow DK, Sung JJ, Wu JC, Tsoi KK, Leong RW, Chan FK. Upper gastrointestinal tract phenotype of Crohn's disease is associated with early surgery and further hospitalization. Inflamm Bowel Dis. 2009;15:551-557. [PMID: 19067420 DOI: 10.1002/ibd.20804] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
560 Balato A, Scala E, Balato N, Caiazzo G, Di Caprio R, Monfrecola G, Raimondo A, Lembo S, Ayala F. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. Expert Opin Biol Ther 2017;17:1363-74. [PMID: 28791896 DOI: 10.1080/14712598.2017.1363884] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
561 Bakleh M, Tleyjeh I, Matteson EL, Osmon DR, Berbari EF. Infectious complications of tumor necrosis factor-α antagonists. Int J Dermatol 2005;44:443-8. [DOI: 10.1111/j.1365-4632.2004.02571.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
562 Fanjiang G, Russell GH, Katz AJ. Short- and Long-term Response to and Weaning from Infliximab Therapy in Pediatric Ulcerative Colitis. Journal of Pediatric Gastroenterology & Nutrition 2007;44:312-7. [DOI: 10.1097/mpg.0b013e31802e98d4] [Cited by in Crossref: 44] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
563 Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, Domènech E, Eliakim R, Eser A, Frater J. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47-91. [PMID: 21172250 DOI: 10.1016/j.crohns.2009.02.010] [Cited by in Crossref: 353] [Cited by in F6Publishing: 316] [Article Influence: 27.2] [Reference Citation Analysis]
564 Van Assche G, Vermeire S, Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin Gastroenterol 2006;22:370-6. [PMID: 16760752 DOI: 10.1097/01.mog.0000231810.87901.e8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
565 Katsanos AH, Katsanos KH. Inflammatory bowel disease and demyelination: more than just a coincidence? Expert Rev Clin Immunol 2014;10:363-73. [PMID: 24490959 DOI: 10.1586/1744666X.2014.885381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
566 Hassan C, Zullo A, Campo SM, Morini S. New insights into the biological therapy of Crohn’s disease. Expert Opinion on Therapeutic Patents 2005;15:409-19. [DOI: 10.1517/13543776.15.4.409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
567 Tschudy J, Michail S. Disseminated Histoplasmosis and Pneumocystis Pneumonia in a Child With Crohn Disease Receiving Infliximab. Journal of Pediatric Gastroenterology & Nutrition 2010;51:221-2. [DOI: 10.1097/mpg.0b013e3181c2c10d] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
568 Bonniaud P, Nunes H. Complications pulmonaires des traitements de la polyarthrite rhumatoïde. Revue des Maladies Respiratoires 2006;23:129-33. [DOI: 10.1016/s0761-8425(06)72017-4] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
569 Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6:1212-1217; quiz 1176. [PMID: 18848503 DOI: 10.1016/j.cgh.2008.05.010] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 6.9] [Reference Citation Analysis]
570 Al-Maawali AK, Nguyen P, Phang PT. Modern Treatments and Stem Cell Therapies for Perianal Crohn's Fistulas. Can J Gastroenterol Hepatol 2016;2016:1651570. [PMID: 28053967 DOI: 10.1155/2016/1651570] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
571 Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit. 2006;28:169-174. [PMID: 16628126 DOI: 10.1097/01.ftd.0000189901.08684.4b] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 5.1] [Reference Citation Analysis]
572 Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:621-31. [PMID: 20594135 DOI: 10.1586/eci.10.36] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
573 Reynolds GJ, Annis KA, de Villiers WJ. Review article: multiple myeloma and inflammatory bowel disease. Dig Dis Sci 2007;52:2022-8. [PMID: 17420948 DOI: 10.1007/s10620-006-9165-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
574 Hasselblatt P, Drognitz K, Potthoff K, Bertz H, Kruis W, Schmidt C, Stallmach A, Schmitt-Graeff A, Finke J, Kreisel W. Remission of refractory Crohn’s disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther. 2012;36:725-735. [PMID: 22937722 DOI: 10.1111/apt.12032] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
575 Stokkers PC, Hommes DW. Novel biological therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:201-10. [PMID: 16901384 DOI: 10.1007/s11938-006-0039-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
576 Huprich JE, Fletcher JG. CT enterography: principles, technique and utility in Crohn’s disease. Eur J Radiol. 2009;69:393-397. [PMID: 19118968 DOI: 10.1016/j.ejrad.2008.11.014] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
577 Rieder F, Kugathasan S. Circulating antibodies against bacterial wall products: are there arguments for early immunosuppression? Dig Dis. 2012;30 Suppl 3:55-66. [PMID: 23295693 DOI: 10.1159/000342603] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]